

KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory

New England Journal of Medicine

382, 1331-1342

DOI: [10.1056/nejmoa1914347](https://doi.org/10.1056/nejmoa1914347)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Advances in chimeric antigen receptor T cells. <i>Current Opinion in Hematology</i> , 2020, 27, 368-377.	1.2	24
2	Long-Term Follow-Up of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy. <i>Journal of Clinical Oncology</i> , 2020, 38, 3805-3815.	0.8	129
3	Nonmyeloablative Conditioning Regimen before T Cell Replete Haploidentical Transplantation with Post-Transplant Cyclophosphamide for Advanced Hodgkin and Non-Hodgkin Lymphomas. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2299-2305.	2.0	4
4	Management of a patient with mantle cell lymphoma who developed severe neurotoxicity after chimeric antigen receptor T-cell therapy in ZUMA-2. , 2020, 8, e001114.		12
5	High-Risk Mantle Cell Lymphoma: Definition, Current Challenges, and Management. <i>Journal of Clinical Oncology</i> , 2020, 38, 4302-4316.	0.8	22
6	Immune recovery in patients with mantle cell lymphoma receiving long-term ibrutinib and venetoclax combination therapy. <i>Blood Advances</i> , 2020, 4, 4849-4859.	2.5	14
7	Chimeric Antigen Receptor T Cell Therapy Delivers Response in Lymphoma Progressing after Allogeneic Transplantation, but is the Sequence Optimal?. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, e211-e212.	2.0	0
8	Complications after CD19+ CAR T-Cell Therapy. <i>Cancers</i> , 2020, 12, 3445.	1.7	32
9	Current Immunotherapy Approaches in Non-Hodgkin Lymphomas. <i>Vaccines</i> , 2020, 8, 708.	2.1	13
10	<p>Sustained Remission of Relapsed or Refractory Mantle Cell Lymphoma After 4-1BB-Based CD19-Directed CAR-T Therapy</p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 12163-12168.	1.0	4
11	Identification of Potent CD19 scFv for CAR T Cells through scFv Screening with NK/T-Cell Line. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9163.	1.8	11
12	C(h)AR-ting a new course in incurable lymphomas: CAR T cells for mantle cell and follicular lymphomas. <i>Blood Advances</i> , 2020, 4, 5858-5862.	2.5	12
13	Immunotherapy with cells (article not eligible for CME credit). <i>Hematology American Society of Hematology Education Program</i> , 2020, 2020, 590-597.	0.9	1
14	Cancer Immunotherapy Using Chimeric Antigen Receptor Expressing T-Cells: Present and Future Needs of Clinical Cancer Centers. <i>Frontiers in Immunology</i> , 2020, 11, 565236.	2.2	9
15	Blastoid Mantle Cell Lymphoma. <i>Hematology/Oncology Clinics of North America</i> , 2020, 34, 941-956.	0.9	17
16	What is the future of immunotherapy in multiple myeloma?. <i>Blood</i> , 2020, 136, 2491-2497.	0.6	22
17	Advances in Classification and Treatment of Non-Hodgkin Lymphoma. <i>Cancer Journal (Sudbury, Mass)</i> , 2020, 26, 348-356.	1.0	2
18	Chemotherapy combinations for B-cell lymphoma and chemo-free approach in elderly patients: an update on best practice. <i>Expert Review of Hematology</i> , 2020, 13, 851-869.	1.0	2

#	ARTICLE	IF	CITATIONS
19	Targeting immune checkpoints in hematological malignancies. <i>Journal of Hematology and Oncology</i> , 2020, 13, 111.	6.9	66
20	<p>Further Understanding of High-Grade Serous Ovarian Carcinogenesis: Potential Therapeutic Targets</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 10423-10437.	0.9	2
21	Immunotherapy in Hematologic Malignancies: Emerging Therapies and Novel Approaches. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8000.	1.8	25
22	Chimeric antigen receptor Tâ€cell therapy for haematological malignancies. <i>Medical Journal of Australia</i> , 2020, 213, 404.	0.8	1
23	High-throughput continuous-flow microfluidic electroporation of mRNA into primary human T cells for applications in cellular therapy manufacturing. <i>Scientific Reports</i> , 2020, 10, 18045.	1.6	37
25	Challenges for immunotherapy for the treatment of platinum resistant ovarian cancer. <i>Seminars in Cancer Biology</i> , 2021, 77, 127-143.	4.3	59
26	The safety of available chemo-free treatments for mantle cell lymphoma. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 1377-1393.	1.0	3
27	Management of Relapsed Mantle Cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, S98-S100.	0.2	0
28	Mantle cell lymphoma: insights into therapeutic targets at the preclinical level. <i>Expert Opinion on Therapeutic Targets</i> , 2020, 24, 1029-1045.	1.5	4
29	Clinical development of cell therapies for cancer: The regulators' perspective. <i>European Journal of Cancer</i> , 2020, 138, 41-53.	1.3	9
30	CD19-directed CAR T-cell therapy in B-cell NHL. <i>Current Opinion in Oncology</i> , 2020, 32, 408-417.	1.1	26
31	Overcoming the Hurdles of Autologous T-Cell-Based Therapies in B-Cell Non-Hodgkin Lymphoma. <i>Cancers</i> , 2020, 12, 3837.	1.7	9
32	Hematopoietic Cell Transplantation and CAR T-Cell Therapy: Complements or Competitors?. <i>Frontiers in Oncology</i> , 2020, 10, 608916.	1.3	13
33	Chimeric Antigen Receptor (CAR)-Modified Immune Effector Cell Therapy for Acute Myeloid Leukemia (AML). <i>Cancers</i> , 2020, 12, 3617.	1.7	7
34	Redirecting cytotoxic T cells with chemically programmed antibodies. <i>Bioorganic and Medicinal Chemistry</i> , 2020, 28, 115834.	1.4	1
35	Advances in CAR T Therapy for Hematologic Malignancies. <i>Pharmacotherapy</i> , 2020, 40, 741-755.	1.2	11
36	Value and affordability of CAR T-cell therapy in the United States. <i>Bone Marrow Transplantation</i> , 2020, 55, 1706-1715.	1.3	66
37	ICU Resource Use in Critically Ill Patients following Chimeric Antigen Receptor T-Cell Therapy. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 202, 1184-1187.	2.5	19

#	ARTICLE	IF	CITATIONS
38	Cost of decentralized <sc>CAR</sc> Tâ€cell production in an academic nonprofit setting. International Journal of Cancer, 2020, 147, 3438-3445.	2.3	45
39	The Advent of CAR T-Cell Therapy for Lymphoproliferative Neoplasms: Integrating Research Into Clinical Practice. Frontiers in Immunology, 2020, 11, 888.	2.2	45
40	CAR T-Cell Therapy for B-Cell non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia: Clinical Trials and Real-World Experiences. Frontiers in Oncology, 2020, 10, 849.	1.3	62
41	Management of Drug Resistance in Mantle Cell Lymphoma. Cancers, 2020, 12, 1565.	1.7	16
42	Emerging therapies in mantle cell lymphoma. Journal of Hematology and Oncology, 2020, 13, 79.	6.9	33
43	CAR T Cells for Mantle Cell Lymphoma: Is it Time to Reshuffle the Deck?. Cancer Cell, 2020, 37, 761-763.	7.7	0
44	Redirecting T Cells against Epsteinâ€Barr Virus Infection and Associated Oncogenesis. Cells, 2020, 9, 1400.	1.8	23
45	Improving the Odds. Biology of Blood and Marrow Transplantation, 2020, 26, e173-e174.	2.0	1
46	KTE-X19 active in MCL. Nature Reviews Clinical Oncology, 2020, 17, 336-336.	12.5	6
47	The chimeric antigen receptor-intensive care unit (CAR-ICU) initiative: Surveying intensive care unit practices in the management of CAR T-cell associated toxicities. Journal of Critical Care, 2020, 58, 58-64.	1.0	31
48	Chimeric antigen receptor (CAR) T-cells on the march: from diffuse large B-cell lymphoma to mantle cell lymphoma. European Journal of Cancer, 2020, 131, 51-52.	1.3	0
49	â€Triple hitâ€<i><sc>SOX</sc>11^{âˆ~}</i>, <sc><i>MME</i></sc>⁺, <sc><i>TP53</i></sc> mutated highâ€grade pleomorphic mantle cell lymphoma. American Journal of Hematology, 2021, 96, 165-166.	2.0	2
50	Outcomes and management of patients with mantle cell lymphoma after progression on brexucabtagene autoleucel therapy. British Journal of Haematology, 2021, 192, e38-e42.	1.2	33
51	Toward Better Understanding and Management of CAR-T Cellâ€Associated Toxicity. Annual Review of Medicine, 2021, 72, 365-382.	5.0	34
52	Delayed neurotoxicity after axicabtagene ciloleucel therapy in relapsed refractory diffuse large B-cell lymphoma. Bone Marrow Transplantation, 2021, 56, 683-685.	1.3	7
53	Yttrium-90 Anti-CD45 Immunotherapy Followed by Autologous Hematopoietic Cell Transplantation for Relapsed or Refractory Lymphoma. Transplantation and Cellular Therapy, 2021, 27, 57.e1-57.e8.	0.6	7
54	Filgrastim associations with <sc>CAR</sc> Tâ€cell therapy. International Journal of Cancer, 2021, 148, 1192-1196.	2.3	21
55	Ibrutinib, obinutuzumab, and venetoclax in relapsed and untreated patients with mantle cell lymphoma: a phase 1/2 trial. Blood, 2021, 137, 877-887.	0.6	68

#	ARTICLE	IF	CITATIONS
56	Taming the beast: CRS and ICANS after CAR T-cell therapy for ALL. Bone Marrow Transplantation, 2021, 56, 552-566.	1.3	113
57	Lymphodepletion strategies to potentiate adoptive T-cell immunotherapy – what are we doing; where are we going?. Expert Opinion on Biological Therapy, 2021, 21, 627-637.	1.4	25
58	Evaluation and management of chimeric antigen receptor (CAR) T-cell-associated neurotoxicity. Neuro-Oncology Practice, 2021, 8, 259-265.	1.0	3
59	CAR-T TREK through the lymphoma universe, to boldly go where no other therapy has gone before. British Journal of Haematology, 2021, 193, 449-465.	1.2	17
60	Cytarabine nanotherapeutics with increased stability and enhanced lymphoma uptake for tailored highly effective therapy of mantle cell lymphoma. Acta Biomaterialia, 2021, 119, 349-359.	4.1	7
61	Late Effects after Chimeric Antigen Receptor T Cell Therapy for Lymphoid Malignancies. Transplantation and Cellular Therapy, 2021, 27, 222-229.	0.6	27
62	CXCR4 in Waldenström's Macroglobulinemia: chances and challenges. Leukemia, 2021, 35, 333-345.	3.3	53
63	Engineering precision therapies: lessons and motivations from the clinic. Synthetic Biology, 2021, 6, ysaa024.	1.2	5
64	Side-effect management of chimeric antigen receptor (CAR) T-cell therapy. Annals of Oncology, 2021, 32, 34-48.	0.6	231
65	High-Risk Mantle Cell Lymphoma in the Era of Novel Agents. Current Hematologic Malignancy Reports, 2021, 16, 8-18.	1.2	5
66	Cost-effectiveness for KTE-X19 CAR T therapy for adult patients with relapsed/refractory mantle cell lymphoma in the United States. Journal of Medical Economics, 2021, 24, 421-431.	1.0	13
67	Emerging Therapies in Relapsed and Refractory Hodgkin Lymphoma: What Comes Next After Brentuximab Vedotin and PD-1 Inhibition?. Current Hematologic Malignancy Reports, 2021, 16, 1-7.	1.2	9
68	Novel therapeutics for patients with well-differentiated gastroenteropancreatic neuroendocrine tumors. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110180.	1.4	21
69	Chimeric Antigen Receptor beyond CAR-T Cells. Cancers, 2021, 13, 404.	1.7	29
70	Allogeneic CAR Cell Therapy – More Than a Pipe Dream. Frontiers in Immunology, 2020, 11, 618427.	2.2	64
71	Recent advances and discoveries in the mechanisms and functions of CAR T cells. Nature Reviews Cancer, 2021, 21, 145-161.	12.8	436
72	Aggressives B-Zell-Lymphom: Registerstudien bestätigen die Wirksamkeit von CAR-T-Zell-Therapien. Karger Kompass Onkologie, 2021, 8, 128-129.	0.0	0
73	Immunotherapy-Associated Cardiotoxicity of Immune Checkpoint Inhibitors and Chimeric Antigen Receptor T Cell Therapy: Diagnostic and Management Challenges and Strategies. Current Cardiology Reports, 2021, 23, 11.	1.3	35

#	ARTICLE	IF	CITATIONS
74	Construction of PD1/CD28 chimeric-switch receptor enhances anti-tumor ability of c-Met CAR-T in gastric cancer. <i>Oncolmmunology</i> , 2021, 10, 1901434.	2.1	34
75	Extranodal blastoid/pleomorphic variant of mantle cell lymphoma involving the testis and skin. <i>BMJ Case Reports</i> , 2021, 14, e239014.	0.2	1
77	Nanomaterials for T-cell cancer immunotherapy. <i>Nature Nanotechnology</i> , 2021, 16, 25-36.	15.6	191
78	Next Generation Therapeutic Strategâ€™es: Evolving cancer immunotherapy through agents that Engage , Expand and Enable the antiâ€™tumor immune response. <i>Immunomedicine</i> , 2021, 1, e1020.	0.7	6
80	IFN Signaling and Myeloid Cells in the Setting of CAR T: A Central Role for the Induction of Endogenous Anti-tumor Immunity. , 2021, 18, .		0
81	The Global Status and Control of Human Schistosomiasis: An Overview. <i>Parasitology Research Monographs</i> , 2021, , 43-51.	0.4	0
82	CARâ€™NK cells: the next wave of cellular therapy for cancer. <i>Clinical and Translational Immunology</i> , 2021, 10, e1274.	1.7	66
83	Clinical characteristics and outcomes of primary versus secondary gastrointestinal mantle cell lymphoma. <i>Blood Cancer Journal</i> , 2021, 11, 8.	2.8	9
84	Selecting the Optimal CAR-T for the Treatment of B-Cell Malignancies. <i>Current Hematologic Malignancy Reports</i> , 2021, 16, 32-39.	1.2	6
85	Immunotherapy and Its Development for Gynecological (Ovarian, Endometrial and Cervical) Tumors: From Immune Checkpoint Inhibitors to Chimeric Antigen Receptor (CAR)-T Cell Therapy. <i>Cancers</i> , 2021, 13, 840.	1.7	17
86	Befriending the Hostile Tumor Microenvironment in CAR T-Cell Therapy. <i>Frontiers in Immunology</i> , 2020, 11, 618387.	2.2	38
87	On the Shoulders of a Giant: Contributions of Thomas Grogan, MD to Hematopathology. <i>Hemato</i> , 2021, 2, 103-115.	0.2	0
88	Recent advances in cellular therapy for malignant lymphoma. <i>Cytotherapy</i> , 2021, 23, 662-671.	0.3	5
89	CAR-T and checkpoint inhibitors: toxicities and antidotes in the emergency department. <i>Clinical Toxicology</i> , 2021, 59, 376-385.	0.8	4
90	GMP-Compliant Universal Antigen Presenting Cells (uAPC) Promote the Metabolic Fitness and Antitumor Activity of Armored Cord Blood CAR-NK Cells. <i>Frontiers in Immunology</i> , 2021, 12, 626098.	2.2	21
91	Utility of a safety switch to abrogate CD19.CAR T-cellâ€™associated neurotoxicity. <i>Blood</i> , 2021, 137, 3306-3309.	0.6	26
92	How I Manage: Pathophysiology and Management of Toxicity of Chimeric Antigen Receptor T-Cell Therapies. <i>Journal of Clinical Oncology</i> , 2021, 39, 456-466.	0.8	21
93	Invited Review: Will Consolidation with ASCT Be a Thing of the Past for MCL and PTCL?. <i>Current Hematologic Malignancy Reports</i> , 2021, 16, 82-88.	1.2	1

#	ARTICLE	IF	CITATIONS
94	Ibrutinib for mantle cell lymphoma at first relapse: a United Kingdom real-world analysis of outcomes in 211 patients. <i>British Journal of Haematology</i> , 2021, 193, 290-298.	1.2	32
95	CRISPR Takes the Front Seat in CART-Cell Development. <i>BioDrugs</i> , 2021, 35, 113-124.	2.2	10
96	Is There Still a Role for Allogeneic Transplantation in the Management of Lymphoma?. <i>Journal of Clinical Oncology</i> , 2021, 39, 487-498.	0.8	27
97	Five-Year Outcomes for Refractory B-Cell Lymphomas with CAR T-Cell Therapy. <i>New England Journal of Medicine</i> , 2021, 384, 673-674.	13.9	178
98	Regulatory challenges and considerations for the clinical application of CAR T cell therapy. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 549-552.	1.4	1
99	Clinicopathologic Findings in Fatal Neurotoxicity After Adoptive Immunotherapy With CD19-Directed CAR T-Cells. <i>HemaSphere</i> , 2021, 5, e533.	1.2	8
100	Prolonged hematologic toxicity following treatment with chimeric antigen receptor T cells in patients with hematologic malignancies. <i>American Journal of Hematology</i> , 2021, 96, 455-461.	2.0	35
101	Outcomes of relapsed mantle cell lymphoma patients after discontinuing acalabrutinib. <i>American Journal of Hematology</i> , 2021, 96, E137-E140.	2.0	6
102	Cell therapies in the clinic. <i>Bioengineering and Translational Medicine</i> , 2021, 6, e10214.	3.9	68
103	The Application of Nanobody in CAR-T Therapy. <i>Biomolecules</i> , 2021, 11, 238.	1.8	44
104	Comprehensive analysis of tumor mutation burden and immune microenvironment in gastric cancer. <i>Bioscience Reports</i> , 2021, 41, .	1.1	19
105	Chimeric Antigen Receptor T-Cell Therapy in the Management of Relapsed Non-Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 476-486.	0.8	8
107	Building a Fit for Purpose Clinical Trials Infrastructure to Accelerate the Assessment of Novel Hematopoietic Cell Transplantation Strategies and Cellular Immunotherapies. <i>Journal of Clinical Oncology</i> , 2021, 39, 534-544.	0.8	6
108	Novel Therapies in the Treatment of Hodgkin Lymphoma. <i>Current Treatment Options in Oncology</i> , 2021, 22, 42.	1.3	5
109	Mantle cell lymphoma – advances in molecular biology, prognostication and treatment approaches. <i>British Journal of Haematology</i> , 2021, 195, 162-173.	1.2	31
110	Engineered CAR-T cells targeting TAG-72 and CD47 in ovarian cancer. <i>Molecular Therapy - Oncolytics</i> , 2021, 20, 325-341.	2.0	40
111	Infiltration of CD163+, PD-L1+ and FoxP3+ positive cells adversely affects outcome in patients with mantle cell lymphoma independent of established risk factors. <i>British Journal of Haematology</i> , 2021, 193, 520-531.	1.2	12
112	Cardiotoxicity Associated with Anti-CD19 Chimeric Antigen Receptor T-Cell (CAR-T) Therapy: Recognition, Risk Factors, and Management. <i>Diseases (Basel, Switzerland)</i> , 2021, 9, 20.	1.0	19

#	ARTICLE	IF	CITATIONS
113	Radiation and CAR T-cell Therapy in Lymphoma: Future Frontiers and Potential Opportunities for Synergy. <i>Frontiers in Oncology</i> , 2021, 11, 648655.	1.3	19
114	Cytokine Release Syndrome Biology and Management. <i>Cancer Journal (Sudbury, Mass)</i> , 2021, 27, 119-125.	1.0	25
115	Resistance to CART cell therapy: lessons learned from the treatment of hematological malignancies. <i>Leukemia and Lymphoma</i> , 2021, 62, 2052-2063.	0.6	16
116	Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study. <i>Lancet, The</i> , 2021, 397, 892-901.	6.3	260
117	The roles of T cell competition and stochastic extinction events in chimeric antigen receptor T cell therapy. <i>Proceedings of the Royal Society B: Biological Sciences</i> , 2021, 288, 20210229.	1.2	22
118	Efficacy and safety of chimeric antigen receptor T cell immunotherapy in B-cell non-Hodgkin lymphoma: a systematic review and meta-analysis. <i>Immunotherapy</i> , 2021, 13, 345-357.	1.0	6
119	Brexucabtagene autoleucel for the treatment of relapsed/refractory mantle cell lymphoma. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 435-441.	1.4	43
120	Relapsed Mantle Cell Lymphoma: Current Management, Recent Progress, and Future Directions. <i>Journal of Clinical Medicine</i> , 2021, 10, 1207.	1.0	11
121	Nanoparticles for Enhanced Adoptive T Cell Therapies and Future Perspectives for CNS Tumors. <i>Frontiers in Immunology</i> , 2021, 12, 600659.	2.2	19
122	Targeting loss of heterozygosity for cancer-specific immunotherapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	39
123	In Vivo CART cell imaging: Paving the way for success in CART cell therapy. <i>Molecular Therapy - Oncolytics</i> , 2021, 20, 625-633.	2.0	14
124	MiRNA-223-3p Affects Mantle Cell Lymphoma Development by Regulating the CHUK/NF- κ B2 Signaling Pathway. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 1553-1564.	1.0	6
125	How should we use ibrutinib in patients with mantle cell lymphoma?. <i>British Journal of Haematology</i> , 2021, 193, 445-446.	1.2	0
126	A single-chain antibody generation system yielding CAR-T cells with superior antitumor function. <i>Communications Biology</i> , 2021, 4, 273.	2.0	14
127	A Review of Chimeric Antigen Receptor T-Cell Therapy for Myeloma and Lymphoma. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 2185-2201.	1.0	9
128	Novel Treatments for Mantle Cell Lymphoma: From Targeted Therapies to CAR T Cells. <i>Drugs</i> , 2021, 81, 669-684.	4.9	2
129	Off-the-Shelf Chimeric Antigen Receptor T Cells. <i>Cancer Journal (Sudbury, Mass)</i> , 2021, 27, 176-181.	1.0	4
130	Chimeric Antigen Receptor Modified Immune Effector Cell Therapies. <i>Cancer Journal (Sudbury, Mass)</i> , 2021, 27, 90-91.	1.0	0

#	ARTICLE	IF	CITATIONS
131	Taking T-Cell Oncotherapy Off-the-Shelf. Trends in Immunology, 2021, 42, 261-272.	2.9	14
132	Carfilzomib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma: A Phase I Trial. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, 139-146.	0.2	6
133	T-cell-based Immunotherapies for Haematological Cancers, Part B: A SWOT Analysis of Adoptive Cell Therapies. Anticancer Research, 2021, 41, 1143-1156.	0.5	11
134	Chimeric Antigen Receptor T Cells for B-Cell Lymphoma. Cancer Journal (Sudbury, Mass), 2021, 27, 107-111.	1.0	3
135	Neurotoxicity Biology and Management. Cancer Journal (Sudbury, Mass), 2021, 27, 126-133.	1.0	7
136	CAR T cell therapy as a promising approach in cancer immunotherapy: challenges and opportunities. Cellular Oncology (Dordrecht), 2021, 44, 495-523.	2.1	32
137	Current status and perspective of CAR-T and CAR-NK cell therapy trials in Germany. Gene Therapy, 2021, 28, 513-527.	2.3	146
138	Tumor Immune Microenvironment during Epithelialâ€“Mesenchymal Transition. Clinical Cancer Research, 2021, 27, 4669-4679.	3.2	138
140	Antibodies to vaccine-preventable infections after CAR-T-cell therapy for B-cell malignancies. JCI Insight, 2021, 6, .	2.3	18
141	Industrializing engineered autologous T cells as medicines for solid tumours. Nature Reviews Drug Discovery, 2021, 20, 476-488.	21.5	12
142	CAR T Cell therapy in solid tumors: a short review. Memo - Magazine of European Medical Oncology, 2021, 14, 143-149.	0.3	17
143	KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results. Blood, 2021, 138, 11-22.	0.6	90
144	Chimeric Antigen Receptorâ€“Modified T Cells and T Cellâ€“Engaging Bispecific Antibodies: Different Tools for the Same Job. Current Hematologic Malignancy Reports, 2021, 16, 218-233.	1.2	4
145	Reactions Related to CAR-T Cell Therapy. Frontiers in Immunology, 2021, 12, 663201.	2.2	54
146	A Systematic Review of the Role of Chimeric Antigen Receptor T (CAR-T) Cell Therapy in the Treatment of Solid Tumors. Cureus, 2021, 13, e14494.	0.2	6
147	2019â€“2020 Drug Updates in Hematologic Malignancies. Journal of the Advanced Practitioner in Oncology, 2021, 12, 279-283.	0.2	2
148	Clinical Cancer Advances 2021: ASCO's Report on Progress Against Cancer. Journal of Clinical Oncology, 2021, 39, 1165-1184.	0.8	54
149	Delivery technologies to engineer natural killer cells for cancer immunotherapy. Cancer Gene Therapy, 2021, 28, 947-959.	2.2	20

#	ARTICLE	IF	CITATIONS
150	Novel agents and regimens for hematological malignancies: recent updates from 2020 ASH annual meeting. <i>Journal of Hematology and Oncology</i> , 2021, 14, 66.	6.9	35
151	A nonviral, nonintegrating DNA nanovector platform for the safe, rapid, and persistent manufacture of recombinant T cells. <i>Science Advances</i> , 2021, 7, .	4.7	43
152	The evolving role of allogeneic haematopoietic cell transplantation in the era of chimaeric antigen receptor Tâ€cell therapy. <i>British Journal of Haematology</i> , 2021, 193, 1060-1075.	1.2	13
154	Allogeneic stem cell transplantation for mantle cell lymphomaâ€” update of the prospective trials of the East German Study Group Hematology/Oncology (OSHO#60 and #74). <i>Annals of Hematology</i> , 2021, 100, 1569-1577.	0.8	6
155	Axicabtagene ciloleucel and brexucabtagene autoleucel in relapsed and refractory diffuse large B-cell and mantle cell lymphomas. <i>Future Oncology</i> , 2021, 17, 1269-1283.	1.1	20
156	Advanced Flow Cytometry Assays for Immune Monitoring of CAR-T Cell Applications. <i>Frontiers in Immunology</i> , 2021, 12, 658314.	2.2	28
157	Cardiovascular Toxicities of CAR T-cell Therapy. <i>Current Oncology Reports</i> , 2021, 23, 78.	1.8	10
158	T-Cell Therapy for Lymphoma Using Nonengineered Multiantigen-Targeted T Cells Is Safe and Produces Durable Clinical Effects. <i>Journal of Clinical Oncology</i> , 2021, 39, 1415-1425.	0.8	30
159	Advanced Therapies and Regulatory Framework in Different Areas of the Globe: Past, Present, and Future. <i>Clinical Therapeutics</i> , 2021, 43, e103-e138.	1.1	9
161	Detection of engineered T cells in FFPE tissue by multiplex in situ hybridization and immunohistochemistry. <i>Journal of Immunological Methods</i> , 2021, 492, 112955.	0.6	1
162	Overview of Cellular Immunotherapies within Transfusion Medicine for the Treatment of Malignant Diseases. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5120.	1.8	0
163	Brexucabtagene autoleucel therapy induces complete remission in a primary refractory blastoid mantle cell lymphoma with neurolymphomatosis. <i>American Journal of Hematology</i> , 2021, 96, E298-E301.	2.0	7
164	CAR T-Cells for CNS Lymphoma: Driving into New Terrain?. <i>Cancers</i> , 2021, 13, 2503.	1.7	15
165	Two Cases of Pancytopenia with Coombs-Negative Hemolytic Anemia after Chimeric Antigen Receptor T-Cell Therapy. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5449.	1.8	3
166	The value of complete remission according to positron emission tomography prior to autologous stem cell transplantation in lymphoma: a population-based study showing improved outcome. <i>BMC Cancer</i> , 2021, 21, 500.	1.1	5
167	Advances in Cellular Immunotherapy in Hematologic Malignancies. <i>Advances in Oncology</i> , 2021, 1, 223-236.	0.1	0
168	Advances in Management for Older Adults With Hematologic Malignancies. <i>Journal of Clinical Oncology</i> , 2021, 39, 2102-2114.	0.8	24
169	Ibrutinib improves the efficacy of antiâ€CD19â€CAR Tâ€cell therapy in patients with refractory nonâ€Hodgkin lymphoma. <i>Cancer Science</i> , 2021, 112, 2642-2651.	1.7	23

#	ARTICLE	IF	CITATIONS
170	Graft-versus-host disease risk after chimeric antigen receptor T-cell therapy: the diametric opposition of T cells. <i>British Journal of Haematology</i> , 2021, 195, 660-668.	1.2	37
171	How Can We Engineer CAR T Cells to Overcome Resistance?. <i>Biologics: Targets and Therapy</i> , 2021, Volume 15, 175-198.	3.0	8
172	Impact of Mantle Cell Lymphoma Contamination of Autologous Stem Cell Grafts on Outcome After High-Dose Chemotherapy. <i>Cancers</i> , 2021, 13, 2558.	1.7	2
173	Cellular Therapies for Mantle Cell Lymphoma. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 363-370.	0.6	6
174	The Potential Role of the Intestinal Micromilieu and Individual Microbes in the Immunobiology of Chimeric Antigen Receptor T-Cell Therapy. <i>Frontiers in Immunology</i> , 2021, 12, 670286.	2.2	16
175	Next-Generation Implementation of Chimeric Antigen Receptor T-Cell Therapy Using Digital Health. <i>JCO Clinical Cancer Informatics</i> , 2021, 5, 668-678.	1.0	20
176	Taking a BiTE out of the CAR T space race. <i>British Journal of Haematology</i> , 2021, 195, 689-697.	1.2	5
177	Balancing Quality, Cost, and Access During Delivery of Newer Cellular and Immunotherapy Treatments. <i>Current Hematologic Malignancy Reports</i> , 2021, 16, 345-356.	1.2	21
178	Anti-CD19 chimeric antigen receptor T-cell therapy in B-cell lymphomas: current status and future directions. <i>International Journal of Hematologic Oncology</i> , 2021, 10, IJH33.	0.7	11
179	Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma. <i>Blood Advances</i> , 2021, 5, 2577-2585.	2.5	60
180	CAR T-Cell Therapy: An Update for Radiologists. <i>American Journal of Roentgenology</i> , 2021, 217, 1461-1474.	1.0	20
181	Turning "Cold" tumors "Hot": immunotherapies in sarcoma. <i>Annals of Translational Medicine</i> , 2021, 9, 1039-1039.	0.7	21
182	CAR T-Cell Therapy in Hematologic Malignancies: Clinical Role, Toxicity, and Unanswered Questions. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2021, 41, e246-e265.	1.8	27
184	CAR T-cell therapy in mature lymphoid malignancies: clinical opportunities and challenges. <i>Annals of Translational Medicine</i> , 2021, 9, 1036-1036.	0.7	3
185	Engineering Gene Therapy: Advances and Barriers. <i>Advanced Therapeutics</i> , 2021, 4, 2100040.	1.6	23
186	Highly Efficient Transfection of Human Primary T Lymphocytes Using Droplet-Enabled Mechanoporation. <i>ACS Nano</i> , 2021, 15, 12888-12898.	7.3	36
187	The "Magic Bullet" Is Here? Cell-Based Immunotherapies for Hematological Malignancies in the Twilight of the Chemotherapy Era. <i>Cells</i> , 2021, 10, 1511.	1.8	3
188	Multidisciplinary Management of Adolescent and Young Adult Patients with Hodgkin Lymphoma. <i>Current Treatment Options in Oncology</i> , 2021, 22, 64.	1.3	3

#	ARTICLE	IF	CITATIONS
189	T-cell receptor-based therapy: an innovative therapeutic approach for solid tumors. <i>Journal of Hematology and Oncology</i> , 2021, 14, 102.	6.9	64
190	Expanded human NK cells armed with CAR uncouple potent anti-tumor activity from off-tumor toxicity against solid tumors. <i>IScience</i> , 2021, 24, 102619.	1.9	33
191	Multifaceted Role of the Transforming Growth Factor β^2 on Effector T Cells and the Implication for CAR-T Cell Therapy. <i>Immuno</i> , 2021, 1, 160-173.	0.6	4
194	SOX11 Inhibitors Are Cytotoxic in Mantle Cell Lymphoma. <i>Clinical Cancer Research</i> , 2021, 27, 4652-4663.	3.2	6
195	Immunotherapy in the treatment of lymphoma. <i>World Journal of Stem Cells</i> , 2021, 13, 503-520.	1.3	3
196	Perspectives in immunotherapy: meeting report from the immunotherapy bridge (December 2nd–3rd,) Tj ETQq1 1.0.784314 rgBT / Ov	1.8	1
197	New targets for CAR T therapy in hematologic malignancies. <i>Best Practice and Research in Clinical Haematology</i> , 2021, 34, 101277.	0.7	9
198	CAR T-Cell Therapy: Updates in Nursing Management. <i>Clinical Journal of Oncology Nursing</i> , 2021, 25, 255-258.	0.3	6
199	Induced Pluripotent Stem Cells (iPSCs) Provide a Potentially Unlimited T Cell Source for CAR-T Cell Development and Off-the-Shelf Products. <i>Pharmaceutical Research</i> , 2021, 38, 931-945.	1.7	18
200	Avoiding Stops and Overcoming Roadblocks: Considerations for Improving Patient Access to CAR-Based Cell Therapies. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2021, 41, e100-e104.	1.8	17
201	Combining selective inhibitors of nuclear export (SINEs) with chimeric antigen receptor (CAR) T cells for CD19-positive malignancies. <i>Oncology Reports</i> , 2021, 46, .	1.2	12
202	Optimizing CAR T cell therapy in lymphoma. <i>Hematological Oncology</i> , 2021, 39, 104-112.	0.8	10
203	Mantle cell lymphoma—Advances in molecular biology, prognostication and treatment approaches. <i>Hematological Oncology</i> , 2021, 39, 31-38.	0.8	8
204	Clinical experience of CAR T cell therapy in lymphomas. <i>Best Practice and Research in Clinical Haematology</i> , 2021, 34, 101281.	0.7	1
205	Toci or not toci: innovations in the diagnosis, prevention, and early management of cytokine release syndrome. <i>Leukemia and Lymphoma</i> , 2021, 62, 2600-2611.	0.6	9
206	CAR-T Cell Therapy: Mechanism, Management, and Mitigation of Inflammatory Toxicities. <i>Frontiers in Immunology</i> , 2021, 12, 693016.	2.2	45
207	CAR T-cell therapy for pleural mesothelioma: Rationale, preclinical development, and clinical trials. <i>Lung Cancer</i> , 2021, 157, 48-59.	0.9	16
208	Novel strategies for immuno-oncology breakthroughs with cell therapy. <i>Biomarker Research</i> , 2021, 9, 62.	2.8	18

#	ARTICLE	IF	CITATIONS
209	Current combinatorial CAR T cell strategies with Bruton tyrosine kinase inhibitors and immune checkpoint inhibitors. <i>Bone Marrow Transplantation</i> , 2021, 56, 2630-2636.	1.3	11
210	T-cell replete allogeneic stem cell transplant for mantle cell lymphoma achieves durable disease control, including against TP53-mutated disease. <i>Bone Marrow Transplantation</i> , 2021, 56, 2857-2859.	1.3	7
211	Acute Kidney Injury Following Chimeric Antigen Receptor T-Cell Therapy for B-Cell Lymphoma in a Kidney Transplant Recipient. <i>Kidney Medicine</i> , 2021, 3, 665-668.	1.0	10
212	Relapsed/Refractory Non-Hodgkin Lymphoma: Engineering T-Cells to Express Chimeric Antigen Receptors (CARs), a Salvage?. <i>Cureus</i> , 2021, 13, e16307.	0.2	3
213	Immunotherapies in Non-Hodgkin's Lymphoma. <i>Cancers</i> , 2021, 13, 3625.	1.7	5
214	Advances in chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma. <i>Biomarker Research</i> , 2021, 9, 58.	2.8	22
215	The B-cell Receptor Autoantigen LRPAP1 Can Replace Variable Antibody Regions to Target Mantle Cell Lymphoma Cells. <i>HemaSphere</i> , 2021, 5, e620.	1.2	5
216	Five year experience in ibrutinib therapy for relapsed and refractory mantle cell lymphoma in real world Russian clinical practice. <i>Terapevticheskii Arkhiv</i> , 2021, 93, 770-777.	0.2	0
217	A comparison of chimeric antigen receptors containing CD28 versus 4-1BB costimulatory domains. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 715-727.	12.5	136
218	Efficacy and Safety of CAR-T Cell Products Axicabtagene Ciloleucel, Tisagenlecleucel, and Lisocabtagene Maraleucel for the Treatment of Hematologic Malignancies: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 698607.	1.3	25
219	Long-term activity of tandem CD19/CD20 CAR therapy in refractory/relapsed B-cell lymphoma: a single-arm, phase 1 trial. <i>Leukemia</i> , 2022, 36, 189-196.	3.3	45
220	Statins act as transient type I interferon inhibitors to enable the antitumor activity of modified vaccinia Ankara viral vectors. , 2021, 9, e001587.		10
221	A deep insight into CRISPR/Cas9 application in CAR-T cell-based tumor immunotherapies. <i>Stem Cell Research and Therapy</i> , 2021, 12, 428.	2.4	63
222	Adoptive cellular therapy in solid tumor malignancies: review of the literature and challenges ahead. , 2021, 9, e002723.		92
223	Strengthening the CAR-T cell therapeutic application using CRISPR/Cas9 technology. <i>Biotechnology and Bioengineering</i> , 2021, 118, 3691-3705.	1.7	13
224	Engineered T Cell Therapy for Gynecologic Malignancies: Challenges and Opportunities. <i>Frontiers in Immunology</i> , 2021, 12, 725330.	2.2	11
225	CAR T and other Adoptive Cell Therapies for B-cell Malignancies. <i>Journal of the National Cancer Center</i> , 2021, , .	3.0	4
226	Overcoming Intrinsic Resistance of Cancer Cells to CAR T-Cell Killing. <i>Clinical Cancer Research</i> , 2021, 27, 6298-6306.	3.2	37

#	ARTICLE	IF	CITATIONS
227	Chimeric Antigen Receptor T Cell Therapy: A Comprehensive Review of Clinical Efficacy, Toxicity, and Best Practices for Outpatient Administration. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 558-570.	0.6	36
228	Critically Ill Patients Treated for Chimeric Antigen Receptor-Related Toxicity: A Multicenter Study*. <i>Critical Care Medicine</i> , 2022, 50, 81-92.	0.4	13
229	Toxicity of Immunotherapeutic Agents. <i>Critical Care Clinics</i> , 2021, 37, 605-624.	1.0	2
230	TNBC: Potential Targeting of Multiple Receptors for a Therapeutic Breakthrough, <i>Nanomedicine, and Immunotherapy</i> . <i>Biomedicines</i> , 2021, 9, 876.	1.4	41
231	Toxicities associated with adoptive cellular therapies. <i>Best Practice and Research in Clinical Haematology</i> , 2021, 34, 101287.	0.7	9
232	Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. <i>Lancet, The</i> , 2021, 398, 314-324.	6.3	711
233	Mantle cell lymphoma patients in first relapse: we pretty much know what to do. <i>Oncotarget</i> , 2021, 12, 1724-1726.	0.8	2
234	T-cell Redirecting Therapies for the Treatment of B-cell Lymphomas: Recent Advances. <i>Cancers</i> , 2021, 13, 4274.	1.7	0
236	In Vivo Cell Tracking Using PET: Opportunities and Challenges for Clinical Translation in Oncology. <i>Cancers</i> , 2021, 13, 4042.	1.7	11
237	Engineering-enhanced CAR T cells for improved cancer therapy. <i>Nature Cancer</i> , 2021, 2, 780-793.	5.7	60
238	Real-World Experiences of CAR T-Cell Therapy for Large B-Cell Lymphoma: How Similar Are They to the Prospective Studies?. <i>Journal of Immunotherapy and Precision Oncology</i> , 2021, 4, 150-159.	0.6	11
239	Brexucabtagene Autoleucel: A Novel Chimeric Antigen Receptor T-cell Therapy for the Treatment of Mantle Cell Lymphoma. <i>Annals of Pharmacotherapy</i> , 2022, 56, 609-619.	0.9	11
240	Advances in Adoptive Cell Therapy for Head and Neck Cancer. <i>Otolaryngologic Clinics of North America</i> , 2021, 54, 761-768.	0.5	9
241	Blood and Marrow Transplant Clinical Trials Network State of the Science Symposium 2021: Looking Forward as the Network Celebrates its 20th Year. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 885-907.	0.6	12
242	Advances in CAR design. <i>Best Practice and Research in Clinical Haematology</i> , 2021, 34, 101304.	0.7	4
243	Antibody and cellular immunotherapies for acute lymphoblastic leukemia in adults. <i>Leukemia and Lymphoma</i> , 2021, 62, 3333-3347.	0.6	2
244	Use of Transcranial Doppler as a Biomarker of CAR T Cell-Related Neurotoxicity. <i>Neurology: Clinical Practice</i> , 2022, 12, 22-28.	0.8	0
245	KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. <i>Lancet, The</i> , 2021, 398, 491-502.	6.3	315

#	ARTICLE	IF	CITATIONS
246	ASTCT, CIBMTR, and EBMT clinical practice recommendations for transplant and cellular therapies in mantle cell lymphoma. <i>Bone Marrow Transplantation</i> , 2021, 56, 2911-2921.	1.3	21
247	Innovations in cancer immunotherapy: chimeric antigen receptor T-cell therapy (CAR-T). <i>Cmaj</i> , 2021, 193, E1300-E1302.	0.9	2
248	Scalable Manufacturing of CAR T Cells for Cancer Immunotherapy. <i>Blood Cancer Discovery</i> , 2021, 2, 408-422.	2.6	84
249	The antibody drug conjugate VLS-101 targeting ROR1 is effective in CAR T-resistant mantle cell lymphoma. <i>Journal of Hematology and Oncology</i> , 2021, 14, 132.	6.9	16
251	Targeting the tumor microenvironment in B-cell lymphoma: challenges and opportunities. <i>Journal of Hematology and Oncology</i> , 2021, 14, 125.	6.9	42
252	Nanobody-armed T cells endow CAR-T cells with cytotoxicity against lymphoma cells. <i>Cancer Cell International</i> , 2021, 21, 450.	1.8	11
253	Strategies to Overcome Failures in T-Cell Immunotherapies by Targeting PI3K- $\hat{\gamma}$ and $\hat{\beta}$. <i>Frontiers in Immunology</i> , 2021, 12, 718621.	2.2	16
254	Pooled safety analysis of tisagenlecleucel in children and young adults with B cell acute lymphoblastic leukemia. , 2021, 9, e002287.		24
255	Targeted immunotherapies to consider for B Cell non-hodgkin lymphoma. <i>Expert Review of Precision Medicine and Drug Development</i> , 2021, 6, 317-332.	0.4	0
256	Current advances in transfusion medicine 2020: A critical review of selected topics by the AABB Clinical Transfusion Medicine Committee. <i>Transfusion</i> , 2021, 61, 2756-2767.	0.8	1
257	Multi-center analysis of practice patterns and outcomes of younger and older patients with mantle cell lymphoma in the rituximab era. <i>American Journal of Hematology</i> , 2021, 96, 1374-1384.	2.0	11
258	Engineering the next generation of CAR-NK immunotherapies. <i>International Journal of Hematology</i> , 2021, 114, 554-571.	0.7	37
259	The Agony of Choice—Where to Place the Wave of BCMA-Targeted Therapies in the Multiple Myeloma Treatment Puzzle in 2022 and Beyond. <i>Cancers</i> , 2021, 13, 4701.	1.7	6
260	Structural engineering of chimeric antigen receptors targeting HLA-restricted neoantigens. <i>Nature Communications</i> , 2021, 12, 5271.	5.8	17
261	Willingness to Travel for Cellular Therapy: The Influence of Follow-Up Care Location, Oncologist Continuity, and Race. <i>JCO Oncology Practice</i> , 2022, 18, e193-e203.	1.4	0
262	American Society of Transplantation and Cellular Therapy, Center of International Blood and Marrow Transplant Research, and European Society for Blood and Marrow Transplantation Clinical Practice Recommendations for Transplantation and Cellular Therapies in Mantle Cell Lymphoma. <i>Transplantation and Cellular Therapy</i> . 2021. 27. 720-728.	0.6	7
263	CD3xCD20 bispecific T-cell redirectors for relapsed or refractory B-cell lymphoma. <i>Lancet, The</i> , 2021, 398, 1109-1110.	6.3	2
264	The EHA Research Roadmap: Immune-based Therapies for Hematological Malignancies. <i>HemaSphere</i> , 2021, 5, e642.	1.2	2

#	ARTICLE	IF	CITATIONS
265	Pushing the boundaries of organs before it's too late: pre-emptive regeneration. <i>Transplant International</i> , 2021, 34, 1761-1769.	0.8	0
266	Incidence and risk factors associated with bleeding and thrombosis following chimeric antigen receptor T-cell therapy. <i>Blood Advances</i> , 2021, 5, 4465-4475.	2.5	28
267	Chimeric Antigen Receptor T-Cell Therapy: An Overview of the Changing Face of Cancer Immunotherapy. <i>Trends in Medical Sciences</i> , 2021, 2, .	0.1	0
268	Extracellular Vesicles Derived from Chimeric Antigen Receptor-T Cells: A Potential Therapy for Cancer. <i>Human Gene Therapy</i> , 2021, 32, 1224-1241.	1.4	24
269	Advances in mRNA-based drug discovery in cancer immunotherapy. <i>Expert Opinion on Drug Discovery</i> , 2022, 17, 41-53.	2.5	17
270	State of the CAR-T: Risk of Infections with Chimeric Antigen Receptor T-Cell Therapy and Determinants of SARS-CoV-2 Vaccine Responses. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 973-987.	0.6	25
271	Novel Treatment Approaches in Relapsed/Refractory Mantle Cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S187-S188.	0.2	1
272	CAR-T therapy: Prospects in targeting cancer stem cells. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 9891-9904.	1.6	16
273	Is Prophylaxis the Only Way Out for Cytokine Release Syndrome Associated With Chimeric Antigen T-cell Therapy?. <i>Cureus</i> , 2021, 13, e17709.	0.2	2
274	Clinical translation of immunomodulatory therapeutics. <i>Advanced Drug Delivery Reviews</i> , 2021, 176, 113896.	6.6	8
275	The promise and perils of immunotherapy. <i>Blood Advances</i> , 2021, 5, 3709-3725.	2.5	23
276	CAR T-Cell Therapies in Mantle Cell Lymphoma, Hints of Cure. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S189-S191.	0.2	2
277	Identifying and managing CAR T-cell-mediated toxicities: on behalf of an Italian CAR-T multidisciplinary team. <i>Expert Opinion on Biological Therapy</i> , 2022, 22, 407-421.	1.4	1
278	Predictors and management of relapse to axicabtagene ciloleucel in patients with aggressive B-cell lymphoma. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2021, , .	0.6	2
279	An autologous culture model of nodal B-cell lymphoma identifies ex vivo determinants of response to bispecific antibodies. <i>Blood Advances</i> , 2021, 5, 5060-5071.	2.5	9
280	Exploiting gene mutations and biomarkers to guide treatment recommendations in mantle cell lymphoma. <i>Expert Review of Hematology</i> , 2021, 14, 1-17.	1.0	2
281	The role of autologous stem cell transplantation (ASCT) in aggressive B-cell lymphomas: real-world data from a retrospective single-center analysis. <i>Annals of Hematology</i> , 2021, 100, 2733-2744.	0.8	7
282	Pembrolizumab for B-cell lymphomas relapsing after or refractory to CD19-directed CAR T-cell therapy. <i>Blood</i> , 2022, 139, 1026-1038.	0.6	67

#	ARTICLE	IF	CITATIONS
283	Genome editing in large animal models. <i>Molecular Therapy</i> , 2021, 29, 3140-3152.	3.7	18
285	Chimeric antigen receptor T-cell therapy: An emergency medicine focused review. <i>American Journal of Emergency Medicine</i> , 2021, 50, 369-375.	0.7	2
286	Comparison of therapeutic strategies for immuno-oncology. , 2022, , 439-461.		0
287	Immune Therapies for Hematologic Malignancies. <i>Cancers</i> , 2021, 13, 295.	1.7	0
288	Gene expression profiling-based risk prediction and profiles of immune infiltration in diffuse large B-cell lymphoma. <i>Blood Cancer Journal</i> , 2021, 11, 2.	2.8	29
289	Adoptive Cell Therapy in Hepatocellular Carcinoma: Biological Rationale and First Results in Early Phase Clinical Trials. <i>Cancers</i> , 2021, 13, 271.	1.7	39
290	Mantle Cell Lymphoma. <i>Hematologic Malignancies</i> , 2021, , 163-178.	0.2	0
292	Allogeneic Stem Cell Transplantation in Mantle Cell Lymphoma in the Era of New Drugs and CAR-T Cell Therapy. <i>Cancers</i> , 2021, 13, 291.	1.7	17
293	Infectious complications of CAR T-cell therapy: a clinical update. <i>Therapeutic Advances in Infectious Disease</i> , 2021, 8, 204993612110367.	1.1	28
294	Detailed Long-Term Follow-Up of Patients Who Relapsed After the Nordic Mantle Cell Lymphoma Trials: MCL2 and MCL3. <i>HemaSphere</i> , 2021, 5, e510.	1.2	18
295	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphoma. , 2020, 8, e001235.		11
296	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events. , 2020, 8, e001511.		138
297	The Influence of Chimeric Antigen Receptor Structural Domains on Clinical Outcomes and Associated Toxicities. <i>Cancers</i> , 2021, 13, 38.	1.7	17
298	Prophylactic Tocilizumab Prior to Anti-CD19 CAR-T Cell Therapy for Non-Hodgkin Lymphoma. <i>Frontiers in Immunology</i> , 2021, 12, 745320.	2.2	41
299	Critical care management of chimeric antigen receptor T cell therapy recipients. <i>Ca-A Cancer Journal for Clinicians</i> , 2022, 72, 78-93.	157.7	29
301	Cellular Therapy Updates in B-Cell Lymphoma: The State of the CAR-T. <i>Cancers</i> , 2021, 13, 5181.	1.7	13
302	Driving Out Chronic Lymphocytic Leukemia With CAR T Cells. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 5-17.	0.6	4
304	CRISPR-derived genome editing therapies: Progress from bench to bedside. <i>Molecular Therapy</i> , 2021, 29, 3125-3139.	3.7	14

#	ARTICLE	IF	CITATIONS
305	CAR T-cell therapy and critical care. Wiener Klinische Wochenschrift, 2021, 133, 1318-1325.	1.0	18
306	Advances in immune therapies in hematological malignancies. Journal of Internal Medicine, 2022, 292, 205-220.	2.7	5
307	The resistance mechanisms and treatment strategies of BTK inhibitors in B-cell lymphoma. Hematological Oncology, 2021, 39, 605-615.	0.8	14
308	Promising Immunotherapeutic Modalities for B-Cell Lymphoproliferative Disorders. International Journal of Molecular Sciences, 2021, 22, 11470.	1.8	6
309	Lisocabtagene maraleucel in relapsed or refractory diffuse large B cell lymphoma: What is the evidence?. Hematology/ Oncology and Stem Cell Therapy, 2021, , .	0.6	5
310	CAR-T in B-cell lymphomas: the past, present and future. Clinical Lymphoma, Myeloma and Leukemia, 2021, , .	0.2	2
311	Promise and pitfalls of allogeneic chimeric antigen receptor therapy in plasma cell and lymphoid malignancies. British Journal of Haematology, 2022, 197, 28-40.	1.2	9
312	Allogeneic stem cell transplantation in patients with mantle cell lymphoma: results from the MANTLE-FIRST study on behalf of Fondazione Italiana Linfomi. Leukemia and Lymphoma, 2021, 62, 3474-3483.	0.6	7
313	The immunologic aspects of cytokine release syndrome and graft versus host disease following CAR T cell therapy. International Reviews of Immunology, 2022, 41, 649-668.	1.5	7
314	Epstein Barr Virus: Development of Vaccines and Immune Cell Therapy for EBV-Associated Diseases. Frontiers in Immunology, 2021, 12, 734471.	2.2	74
315	Adverse Cardiovascular and Pulmonary Events Associated With Chimeric Antigen Receptor T-Cell Therapy. Journal of the American College of Cardiology, 2021, 78, 1800-1813.	1.2	55
316	Concurrent ibrutinib plus venetoclax in relapsed/refractory mantle cell lymphoma: the safety run-in of the phase 3 SYMPATICO study. Journal of Hematology and Oncology, 2021, 14, 179.	6.9	33
317	Systematic review of nutrition support interventions in adult haematology and oncology patients receiving CAR T cell therapy. Clinical Nutrition ESPEN, 2021, 46, 60-65.	0.5	3
318	Regulating innovation in the early development of cell therapies. Immunotherapy Advances, 2021, 1, .	1.2	2
319	Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Mantle Cell Lymphoma: Is It Time to Consider CAR-T for All?. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 1764-1766.	2.3	0
320	Barriers to achieving a cure in lymphoma. , 2021, 4, 965-983.		0
321	Severe cytokine release syndrome is associated with hematologic toxicity following CD19 CAR T-cell therapy. Blood Advances, 2022, 6, 2055-2068.	2.5	60
322	Pretherapy metabolic tumor volume is associated with response to CD30 CAR T cells in Hodgkin lymphoma. Blood Advances, 2022, 6, 1255-1263.	2.5	26

#	ARTICLE	IF	CITATIONS
323	Therapeutic options for relapsed/refractory mantle cell lymphoma. <i>Blood</i> , 2022, 139, 666-677.	0.6	27
324	Genetically Modified T Cells for Esophageal Cancer Therapy: A Promising Clinical Application. <i>Frontiers in Oncology</i> , 2021, 11, 763806.	1.3	6
326	Non-Hodgkin-Lymphome. , 2022, , 195-203.		0
327	Influence of TP53 Mutation on Survival of Diffuse Large B-Cell Lymphoma in the CAR T-Cell Era. <i>Cancers</i> , 2021, 13, 5592.	1.7	9
328	How to Diagnose and Treat CD5-Positive Lymphomas Involving the Spleen. <i>Current Oncology</i> , 2021, 28, 4611-4633.	0.9	4
329	CAR-T-OPENIA: Chimeric antigen receptor T-cell therapy-associated cytopenias. <i>EJHaem</i> , 2022, 3, 32-38.	0.4	16
330	NCCN Guidelines® Insights: B-Cell Lymphomas, Version 5.2021. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 1218-1230.	2.3	98
331	Born to survive: how cancer cells resist CAR T cell therapy. <i>Journal of Hematology and Oncology</i> , 2021, 14, 199.	6.9	59
332	Mantle cell lymphoma: A clinical review of the changing treatment paradigms with the advent of novel therapies, and an insight into Indian data. <i>Cancer Reports</i> , 2021, , e1590.	0.6	3
333	Immunotherapy for Tumor Metastasis by Artificial Antigen-Presenting Cells via Targeted Microenvironment Regulation and T-Cell Activation. <i>ACS Applied Materials & Interfaces</i> , 2021, 13, 55890-55901.	4.0	16
334	Overview of approved CAR-T therapies, ongoing clinical trials, and its impact on clinical practice. <i>EJHaem</i> , 2022, 3, 6-10.	0.4	63
335	Outcome of patients with mantle cell lymphoma after autologous stem cell transplantation in the pre-CAR T-cell era. <i>Hematological Oncology</i> , 2022, 40, 292-296.	0.8	6
336	AssociaÃ§Ã£o Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. III: anti-CD19 CAR-T cell therapy for patients with non-Hodgkin lymphoma. <i>Hematology, Transfusion and Cell Therapy</i> , 2021, 43, S22-S29.	0.1	0
337	Current Knowledge in Genetics, Molecular Diagnostic Tools, and Treatments for Mantle Cell Lymphomas. <i>Frontiers in Oncology</i> , 2021, 11, 739441.	1.3	3
338	Emerging Approaches for Solid Tumor Treatment Using CAR-T Cell Therapy. <i>International Journal of Molecular Sciences</i> , 2021, 22, 12126.	1.8	8
339	Payload Delivery: Engineering Immune Cells to Disrupt the Tumour Microenvironment. <i>Cancers</i> , 2021, 13, 6000.	1.7	3
340	New indications and platforms for CAR-T therapy in lymphomas beyond DLBCL. <i>EJHaem</i> , 2022, 3, 11-23.	0.4	2
341	Role of bridging therapy during chimeric antigen receptor T cell therapy. <i>EJHaem</i> , 2022, 3, 39-45.	0.4	9

#	ARTICLE	IF	CITATIONS
342	Mantle Cell Lymphoma: Updates in the Management of Relapsed/Refractory Disease. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 1331-1333.	2.3	0
343	Sequencing of Novel Therapies for Mantle Cell Lymphoma. Current Treatment Options in Oncology, 2021, 22, 118.	1.3	3
344	CAR Treg: A new approach in the treatment of autoimmune diseases. International Immunopharmacology, 2022, 102, 108409.	1.7	12
345	Disease-specific outcomes after chimeric antigen receptor T-cell therapy. European Journal of Cancer, 2021, , .	1.3	2
346	Idecabtagene vicleucel (ide-cel) CAR T-cell therapy for relapsed and refractory multiple myeloma. Future Oncology, 2022, 18, 277-289.	1.1	20
347	Antigen multimers: Specific, sensitive, precise, and multifunctional high-avidity CAR-staining reagents. Matter, 2021, 4, 3917-3940.	5.0	4
348	Neurologic Toxicities of Immunotherapy. Advances in Experimental Medicine and Biology, 2021, 1342, 417-429.	0.8	2
349	External stimuli-responsive nanomedicine for cancer immunotherapy. , 2021, , .		0
350	Applications of CRISPR-Cas System in Tumor Biology. Oncologie, 2021, 23, 463-492.	0.2	1
351	Managing Relapsed Mantle Cell Lymphoma. Clinical Lymphoma, Myeloma and Leukemia, 2022, , .	0.2	2
352	Single-center experience using anakinra for steroid-refractory immune effector cell-associated neurotoxicity syndrome (ICANS). , 2022, 10, e003847.		44
354	The emerging roles of NGS in clinical oncology and personalized medicine. Pathology Research and Practice, 2022, 230, 153760.	1.0	25
356	CAR-T cells, from principle to clinical applications. Bulletin Du Cancer, 2021, 108, S4-S17.	0.6	15
359	Primary Effusion Lymphoma: A Clinicopathologic Perspective. Cancers, 2022, 14, 722.	1.7	9
360	Adverse effects in hematologic malignancies treated with chimeric antigen receptor (CAR) T cell therapy: a systematic review and Meta-analysis. BMC Cancer, 2022, 22, 98.	1.1	15
361	Engineered T Cells: CAR T Cell Therapy and Beyond. Current Oncology Reports, 2022, 24, 23-31.	1.8	23
362	Immunotherapeutic Strategies in Cancer and Atherosclerosisâ€”Two Sides of the Same Coin. Frontiers in Cardiovascular Medicine, 2021, 8, 812702.	1.1	2
363	Chimeric Antigen Receptor T-Cell Therapy in Paediatric B-Cell Precursor Acute Lymphoblastic Leukaemia: Curative Treatment Option or Bridge to Transplant?. Frontiers in Pediatrics, 2021, 9, 784024.	0.9	13

#	ARTICLE	IF	CITATIONS
364	Neurofilament light chain serum levels correlate with the severity of neurotoxicity after CAR T-cell treatment. <i>Blood Advances</i> , 2022, 6, 3022-3026.	2.5	13
365	Enhanced Chimeric Antigen Receptor T Cell Therapy through Co-Application of Synergistic Combination Partners. <i>Biomedicines</i> , 2022, 10, 307.	1.4	9
366	Inhibition of Calcium Signaling Prevents Exhaustion and Enhances Anti-Leukemia Efficacy of CAR-T Cells via SOCE-Calcineurin-NFAT and Glycolysis Pathways. <i>Advanced Science</i> , 2022, 9, e2103508.	5.6	21
368	Novel Treatment Approaches in Relapsed/Refractory Mantle Cell Lymphoma: Highlights From SOHO 2021. <i>Journal of the Advanced Practitioner in Oncology</i> , 2022, 13, 37-40.	0.2	0
369	Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial. <i>Lancet Oncology</i> , The, 2022, 23, 91-103.	5.1	236
370	The Evolving Role of Allogeneic Stem Cell Transplant in the Era of Molecularly Targeted Agents. <i>Cancer Journal (Sudbury, Mass)</i> , 2022, 28, 78-84.	1.0	0
371	Effect of early granulocyte-colony-stimulating factor administration in the prevention of febrile neutropenia and impact on toxicity and efficacy of anti-CD19 CAR-T in patients with relapsed/refractory B-cell lymphoma. <i>Bone Marrow Transplantation</i> , 2022, 57, 431-439.	1.3	26
372	Hematopoietic cell transplantation for mantle cell lymphoma. <i>International Journal of Hematology</i> , 2022, 115, 301.	0.7	0
373	Development of a Novel Anti-CD19 CAR Containing a Fully Human scFv and Three Costimulatory Domains. <i>Frontiers in Oncology</i> , 2021, 11, 802876.	1.3	8
374	Blinatumomab in pediatric relapsed/refractory B-cell acute lymphoblastic leukemia: RIALTO expanded access study final analysis. <i>Blood Advances</i> , 2022, 6, 1004-1014.	2.5	22
375	Targeted Drug Delivery and Theranostic Strategies in Malignant Lymphomas. <i>Cancers</i> , 2022, 14, 626.	1.7	11
376	Roadmap for Starting an Outpatient Cellular Therapy Program. <i>Cancer Drug Discovery and Development</i> , 2022, , 355-368.	0.2	0
377	Ibrutinib-rituximab followed by R-HCVAD as frontline treatment for young patients (>65 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial. <i>Lancet Oncology</i> , The, 2022, 23, 406-415.	5.1	22
378	Prospect of CAR T-cell therapy in acute myeloid leukemia. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 211-220.	1.9	4
379	Current global trends in the development of CAR-T therapy. <i>Journal of Illusion</i> , 2022, 11, 1-9.	0.0	0
381	The next wave of cellular immunotherapies in pancreatic cancer. <i>Molecular Therapy - Oncolytics</i> , 2022, 24, 561-576.	2.0	34
382	Extensive myelitis with eosinophilic meningitis after Chimeric antigen receptor T cells therapy. <i>EJHaem</i> , 2022, 3, 533-536.	0.4	2
383	Anti-CAIX BB-2714 CAR4/8 T cells exhibit superior efficacy in a ccRCC mouse model. <i>Molecular Therapy - Oncolytics</i> , 2022, 24, 385-399.	2.0	15

#	ARTICLE	IF	CITATIONS
384	Post-CAR-T Cell Therapy (Consolidation and Relapse): Lymphoma. , 2022, , 169-171.		1
385	In vivo experimental mouse model to test CD19CAR T cells generated with different methods. <i>Methods in Cell Biology</i> , 2022, 167, 149-161.	0.5	3
386	Pharmacological Aspects of Clinically Approved Gene Therapy Drugs and Products. , 2022, , .		0
389	Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study. <i>Journal of Clinical Oncology</i> , 2022, 40, 481-491.	0.8	160
390	Emerging drug targets for colon cancer: A preclinical assessment. <i>Expert Opinion on Therapeutic Targets</i> , 2022, 26, 207-216.	1.5	4
391	Management of haemostatic complications of chimaeric antigen receptor T cell therapy. <i>British Journal of Haematology</i> , 2022, 197, 250-259.	1.2	0
392	Synthetic Biology-based Optimization of T cell Immunotherapies for Cancer. <i>Current Opinion in Biomedical Engineering</i> , 2022, 22, 100372.	1.8	0
393	Multipurposing CARs: Same engine, different vehicles. <i>Molecular Therapy</i> , 2022, 30, 1381-1395.	3.7	9
394	Challenges of chimeric antigen receptor T-cell therapy in chronic lymphocytic leukemia: lessons learned. <i>Experimental Hematology</i> , 2022, 108, 1-7.	0.2	9
395	Update on Molecular Diagnosis in Extranodal NK/T-Cell Lymphoma and Its Role in the Era of Personalized Medicine. <i>Diagnostics</i> , 2022, 12, 409.	1.3	5
396	Engineering CAR-NK cells: how to tune innate killer cells for cancer immunotherapy. <i>Immunotherapy Advances</i> , 2022, 2, .	1.2	6
397	Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA). <i>Annals of Oncology</i> , 2022, 33, 259-275.	0.6	139
398	Robust T cell activation requires an eIF3-driven burst in T cell receptor translation. <i>ELife</i> , 2021, 10, .	2.8	14
399	An orthogonal IL-2 and IL-2R β system drives persistence and activation of CAR T cells and clearance of bulky lymphoma. <i>Science Translational Medicine</i> , 2021, 13, eabg7565.	5.8	37
400	Modified T cells as therapeutic agents. <i>Hematology American Society of Hematology Education Program</i> , 2021, 2021, 296-302.	0.9	3
401	The Anti-CD19 Antibody-Drug Conjugate Loncastuximab Tesirine. <i>Touch Reviews in Oncology & Haematology</i> , 2021, 17, 95.	0.1	0
402	Recent advances in the prevention and management of cytokine release syndrome after chimeric antigen receptor T-cell therapy. <i>European Journal of Inflammation</i> , 2022, 20, 1721727X2210787.	0.2	0
403	Chimeric antigen receptor (CAR) T-cell treatment for mantle cell lymphoma (MCL). <i>Therapeutic Advances in Hematology</i> , 2022, 13, 204062072210807.	1.1	7

#	ARTICLE	IF	CITATIONS
404	Advances in the Treatment of Hairy Cell Leukemia Variant. <i>Current Treatment Options in Oncology</i> , 2022, 23, 99-116.	1.3	1
405	A durable 4-1BB-based CD19 CAR-T cell for treatment of relapsed or refractory non-Hodgkin lymphoma. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2022, 34, 53-62.	0.7	4
406	Mantle cell lymphoma management trends and novel agents: where are we going?. <i>Therapeutic Advances in Hematology</i> , 2022, 13, 204062072210807.	1.1	8
407	Radiation and Chimeric Antigen Receptor T-cell Therapy in B-cell Non-Hodgkin Lymphomas. <i>Current Treatment Options in Oncology</i> , 2022, 23, 89-98.	1.3	3
408	Multifunctional theranostic nanoparticles for multi-modal imaging-guided CAR-T immunotherapy and chemo-photothermal combinational therapy of non-Hodgkin's lymphoma. <i>Biomaterials Science</i> , 2022, 10, 2577-2589.	2.6	10
410	Cellular Therapy Advances in Chronic Lymphocytic Leukemia and Richter's Syndrome. <i>Current Problems in Cancer</i> , 2022, 46, 100827.	1.0	1
412	Increased visceral fat distribution and body composition impact cytokine release syndrome onset and severity after CD19 chimeric antigen receptor T-cell therapy in advanced B-cell malignancies. <i>Haematologica</i> , 2022, 107, 2096-2107.	1.7	17
413	CD19-directed chimeric antigen receptor T cell therapy in Waldenström macroglobulinemia: a preclinical model and initial clinical experience. , 2022, 10, e004128.		18
414	Targeting of the alpha _v beta ₃ integrin complex by CAR-T cells leads to rapid regression of diffuse intrinsic pontine glioma and glioblastoma. , 2022, 10, e003816.		24
415	Bispecific Antibodies for Non-Hodgkin Lymphoma Treatment. <i>Current Treatment Options in Oncology</i> , 2022, 23, 155-170.	1.3	17
416	Engineering T-cells with chimeric antigen receptors to combat hematological cancers: an update on clinical trials. <i>Cancer Immunology, Immunotherapy</i> , 2022, , 1.	2.0	5
417	A multicenter phase II study of bendamustine, rituximab, and cytarabine (BRAC) for relapsed or refractory patients with follicular lymphoma or mantle cell lymphoma. <i>Experimental Hematology and Oncology</i> , 2022, 11, 9.	2.0	2
418	Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucl in CARTITUDE studies. <i>Blood Cancer Journal</i> , 2022, 12, 32.	2.8	73
419	Clinical Grade Manufacture of CYAD-101, a NKG2D-based, First in Class, Non-“Gene-edited Allogeneic CAR T-Cell Therapy. <i>Journal of Immunotherapy</i> , 2022, 45, 150-161.	1.2	14
420	Prospect of Prostate Cancer Treatment: Armed CAR-T or Combination Therapy. <i>Cancers</i> , 2022, 14, 967.	1.7	5
421	CAR T-cell therapy for B-cell lymphoma. <i>Current Problems in Cancer</i> , 2022, 46, 100826.	1.0	26
422	The Two-Step Allogeneic Stem Cell Transplantation Approach Results in Rapid Engraftment and Excellent Outcomes in Patients with Lymphoid Malignancies. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 159.e1-159.e5.	0.6	2
423	Two for one: targeting BCMA and CD19 in B-cell malignancies with off-the-shelf dual-CAR NK-92 cells. <i>Journal of Translational Medicine</i> , 2022, 20, 124.	1.8	21

#	ARTICLE	IF	CITATIONS
424	Cytopenia after CAR-T Cell Therapy—A Brief Review of a Complex Problem. <i>Cancers</i> , 2022, 14, 1501.	1.7	43
425	Allogeneic Anti-BCMA CAR T Cells Are Superior to Multiple Myeloma-derived CAR T Cells in Preclinical Studies and May Be Combined with Gamma Secretase Inhibitors. <i>Cancer Research Communications</i> , 2022, 2, 158-171.	0.7	8
426	The Future of Natural Killer Cell Immunotherapy for B Cell Non-Hodgkin Lymphoma (B Cell NHL). <i>Current Treatment Options in Oncology</i> , 2022, 23, 381-403.	1.3	5
427	Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy. <i>Nature Medicine</i> , 2022, 28, 713-723.	15.2	117
428	Relapsed/Refractory Mantle Cell Lymphoma: Beyond BTK Inhibitors. <i>Journal of Personalized Medicine</i> , 2022, 12, 376.	1.1	9
429	Clinical Presentation, Risk Factors, and Outcomes of Immune Effector Cell-Associated Neurotoxicity Syndrome Following Chimeric Antigen Receptor T Cell Therapy: A Systematic Review. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 294-302.	0.6	17
430	Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial. <i>Nature Medicine</i> , 2022, 28, 735-742.	15.2	114
431	Cardiotoxicity from chimeric antigen receptor-T cell therapy for advanced malignancies. <i>European Heart Journal</i> , 2022, 43, 1928-1940.	1.0	39
432	Genetic Modification of T Cells for the Immunotherapy of Cancer. <i>Vaccines</i> , 2022, 10, 457.	2.1	2
433	<i>In Vivo</i> Cellular Expansion of Lisocabtagene Maraleucel and Association With Efficacy and Safety in Relapsed/Refractory Large B-Cell Lymphoma. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 112, 81-89.	2.3	14
434	Real-world evidence of brexucabtagene autoleucel for the treatment of relapsed or refractory mantle cell lymphoma. <i>Blood Advances</i> , 2022, 6, 3606-3610.	2.5	35
435	Cost-Effectiveness of Brexucabtagene Autoleucel versus Best Supportive Care for the Treatment of Relapsed/Refractory Mantle Cell Lymphoma following Treatment with a Bruton's Tyrosine Kinase Inhibitor in Canada. <i>Current Oncology</i> , 2022, 29, 2021-2045.	0.9	6
436	Improving the Safety of Mesenchymal Stem Cell-Based Ex Vivo Therapy Using Herpes Simplex Virus Thymidine Kinase. <i>Molecules and Cells</i> , 2022, 45, 479-494.	1.0	4
437	CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, 119.	3.5	167
438	Monitoring of Circulating CAR T Cells: Validation of a Flow Cytometric Assay, Cellular Kinetics, and Phenotype Analysis Following Tisagenlecleucel. <i>Frontiers in Immunology</i> , 2022, 13, 830773.	2.2	21
439	Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 342-355.	12.5	113
440	Donor T cells for CAR T cell therapy. <i>Biomarker Research</i> , 2022, 10, 14.	2.8	9
441	Chimeric antigen receptor T-cell therapy for relapsed mantle cell lymphoma: real-world experience from a single tertiary care center. <i>Bone Marrow Transplantation</i> , 2022, 57, 1010-1012.	1.3	6

#	ARTICLE	IF	CITATIONS
442	Identification of NOXA as a pivotal regulator of resistance to CAR T-cell therapy in B-cell malignancies. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 98.	7.1	19
443	EASIX and Severe Endothelial Complications After CD19-Directed CAR-T Cell Therapy—A Cohort Study. <i>Frontiers in Immunology</i> , 2022, 13, 877477.	2.2	17
444	Reversing chemokine/chemokine receptor mismatch to enhance the antitumor efficacy of CAR-T cells. <i>Immunotherapy</i> , 2022, 14, 459-473.	1.0	3
445	Mantle cell lymphoma in 2022—A comprehensive update on molecular pathogenesis, risk stratification, clinical approach, and current and novel treatments. <i>American Journal of Hematology</i> , 2022, 97, 638-656.	2.0	48
446	Acute and delayed cytopenias following CAR T-cell therapy: an investigation of risk factors and mechanisms. <i>Leukemia and Lymphoma</i> , 2022, 63, 1849-1860.	0.6	14
447	Managing hypogammaglobulinemia in patients treated with CAR-T-cell therapy: key points for clinicians. <i>Expert Review of Hematology</i> , 2022, 15, 305-320.	1.0	25
448	Outcome of COVID-19 in Patients With Mantle Cell Lymphoma—Report From the European MCL Registry. <i>HemaSphere</i> , 2022, 6, e0711.	1.2	7
449	Anti-PD-1 Therapy Enhances the Efficacy of CD30-Directed Chimeric Antigen Receptor T Cell Therapy in Patients With Relapsed/Refractory CD30+ Lymphoma. <i>Frontiers in Immunology</i> , 2022, 13, 858021.	2.2	23
450	Stem cell transplant for mantle cell lymphoma in Taiwan. <i>Scientific Reports</i> , 2022, 12, 5662.	1.6	3
451	Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, 387-405.	2.3	124
452	Immunotherapy-Related Acute Kidney Injury. <i>Advances in Chronic Kidney Disease</i> , 2021, 28, 429-437.e1.	0.6	5
453	Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 367.	3.5	72
454	Strategies to Circumvent the Side-Effects of Immunotherapy Using Allogeneic CAR-T Cells and Boost Its Efficacy: Results of Recent Clinical Trials. <i>Frontiers in Immunology</i> , 2021, 12, 780145.	2.2	11
455	Tuning the ignition of CAR: optimizing the affinity of scFv to improve CAR-T therapy. <i>Cellular and Molecular Life Sciences</i> , 2022, 79, 14.	2.4	27
457	Tumor-Associated Neutrophil Extracellular Traps Regulating Nanocarrier-Enhanced Inhibition of Malignant Tumor Growth and Distant Metastasis. <i>ACS Applied Materials & Interfaces</i> , 2021, 13, 59683-59694.	4.0	17
458	Natural Receptor- and Ligand-Based Chimeric Antigen Receptors: Strategies Using Natural Ligands and Receptors for Targeted Cell Killing. <i>Cells</i> , 2022, 11, 21.	1.8	16
459	Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Look at the Approved and Emerging Therapies. <i>Journal of Personalized Medicine</i> , 2021, 11, 1345.	1.1	19
460	CAR T-cell immunotherapy: a powerful weapon for fighting hematological B-cell malignancies. <i>Frontiers of Medicine</i> , 2021, 15, 783-804.	1.5	3

#	ARTICLE	IF	CITATIONS
461	Prognostic Significance of Cytokine Release Syndrome in B Cell Hematological Malignancies Patients After Chimeric Antigen Receptor T Cell Therapy. <i>Journal of Interferon and Cytokine Research</i> , 2021, 41, 469-476.	0.5	9
462	Allogeneic Chimeric Antigen Receptor Therapy in Lymphoma. <i>Current Treatment Options in Oncology</i> , 2022, 23, 171-187.	1.3	9
463	Chimeric antigen receptor T-cell therapy in adult patients with B-cell lymphoproliferative diseases. <i>Gematologiya I Transfuziologiya</i> , 2022, 67, 8-28.	0.1	1
464	Socioeconomic and Racial Disparity in Chimeric Antigen Receptor T Cell Therapy Access. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 358-364.	0.6	40
465	Enrollment of Black Participants in Pivotal Clinical Trials Supporting US Food and Drug Administration Approval of Chimeric Antigen Receptor T Cell Therapy for Hematological Malignant Neoplasms. <i>JAMA Network Open</i> , 2022, 5, e228161.	2.8	22
466	CAR T cell killing requires the IFN γ R pathway in solid but not liquid tumours. <i>Nature</i> , 2022, 604, 563-570.	13.7	150
467	CAR T-Cell Therapy in the Older Person: Indications and Risks. <i>Current Oncology Reports</i> , 2022, 24, 1189-1199.	1.8	11
468	Development of CAR T Cell Therapy in Children—A Comprehensive Overview. <i>Journal of Clinical Medicine</i> , 2022, 11, 2158.	1.0	12
469	Safety and feasibility of outpatient chimeric antigen receptor (CAR) T-cell therapy: experience from a tertiary care center. <i>Bone Marrow Transplantation</i> , 2022, 57, 1025-1027.	1.3	27
470	Impact of CD19 CAR T-cell product type on outcomes in relapsed or refractory aggressive B-NHL. <i>Blood</i> , 2022, 139, 3722-3731.	0.6	28
471	Chronic Lymphocytic Leukemia: Chemotherapy Free and Other Novel Therapies Including CAR T. <i>Current Treatment Options in Oncology</i> , 2022, 23, 904.	1.3	4
472	Modulating tumor physical microenvironment for fueling CAR-T cell therapy. <i>Advanced Drug Delivery Reviews</i> , 2022, 185, 114301.	6.6	28
473	Non-cleavable hinge enhances avidity and expansion of CAR-T cells for acute myeloid leukemia. <i>Cancer Cell</i> , 2022, 40, 494-508.e5.	7.7	54
474	Novel treatments in B cell non-Hodgkin's lymphomas. <i>BMJ, The</i> , 2022, 377, e063439.	3.0	5
475	Chimeric Antigen Receptor (CAR) T Cell Therapy for Glioblastoma. <i>Cancer Treatment and Research</i> , 2022, 183, 161-184.	0.2	2
476	Impact of Consolidative Unrelated Cord Blood Transplantation on Clinical Outcomes of Patients With Relapsed/Refractory Acute B Lymphoblastic Leukemia Entering Remission Following CD19 Chimeric Antigen Receptor T Cells. <i>Frontiers in Immunology</i> , 2022, 13, 879030.	2.2	1
477	2020–2021 Drug Updates in Hematologic Malignancies. <i>Journal of the Advanced Practitioner in Oncology</i> , 2022, 13, 282-285.	0.2	0
478	Efficacy and safety of CAR-T cell therapy in minorities. <i>Bone Marrow Transplantation</i> , 2022, , .	1.3	0

#	ARTICLE	IF	CITATIONS
479	Approval of brexucabtagene autoleucel for adults with relapsed and refractory acute lymphocytic leukemia. <i>Blood</i> , 2022, 140, 11-15.	0.6	23
480	Demographic differences among patients treated with chimeric antigen receptor <sc>T cell</sc> therapy in the United States. <i>Cancer Medicine</i> , 2022, 11, 4440-4448.	1.3	6
481	Systematic review and meta-analysis of the association between bridging therapy and outcomes of chimeric antigen receptor T cell therapy in patients with large B cell lymphoma. <i>Cytotherapy</i> , 2022, 24, 940-953.	0.3	5
482	Chimeric Antigen Receptor Based Cellular Therapy for Treatment Of T-Cell Malignancies. <i>Frontiers in Oncology</i> , 2022, 12, .	1.3	11
483	The translational challenges of precision oncology. <i>Cancer Cell</i> , 2022, 40, 458-478.	7.7	38
484	CAR T cell manufacturing from naive/stem memory T lymphocytes enhances antitumor responses while curtailing cytokine release syndrome. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	66
485	Enhanced safety and efficacy of protease-regulated CAR-T cell receptors. <i>Cell</i> , 2022, 185, 1745-1763.e22.	13.5	88
486	Enhanced AC133-specific CAR T cell therapy induces durable remissions in mice with metastatic small cell lung cancer. <i>Cancer Letters</i> , 2022, 538, 215697.	3.2	16
487	Self-assembled polysaccharide nanogel delivery system for overcoming tumor immune resistance. <i>Journal of Controlled Release</i> , 2022, 347, 175-182.	4.8	22
488	New Directions for Mantle Cell Lymphoma in 2022. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2022, 42, 614-628.	1.8	14
489	Neuroimaging findings in immune effector cell associated neurotoxicity syndrome after chimeric antigen receptor T-cell therapy. <i>Leukemia and Lymphoma</i> , 2022, 63, 2364-2374.	0.6	6
490	IBRORS-MCL study: a Spanish retrospective and observational study of relapsed/refractory mantle-cell lymphoma treated with ibrutinib in routine clinical practice. <i>International Journal of Hematology</i> , 2022, , .	0.7	0
491	Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022. <i>Bone Marrow Transplantation</i> , 2022, 57, 1217-1239.	1.3	119
492	Time 2EVOLVE: predicting efficacy of engineered T-cells “ how far is the bench from the bedside?. , 2022, 10, e003487.		13
493	Enabling CAR-T cells for solid tumors: Rage against the suppressive tumor microenvironment. <i>International Review of Cell and Molecular Biology</i> , 2022, , 123-147.	1.6	8
494	A cauldron of choices. <i>Blood</i> , 2022, 139, 3103-3104.	0.6	0
495	Developing lisocabtagene maraleucel chimeric antigen receptor T-cell manufacturing for improved process, product quality and consistency across CD19+ hematologic indications. <i>Cytotherapy</i> , 2022, 24, 962-973.	0.3	6
496	CAR T Cell Therapy for Chronic Lymphocytic Leukemia: Successes and Shortcomings. <i>Current Oncology</i> , 2022, 29, 3647-3657.	0.9	18

#	ARTICLE	IF	CITATIONS
497	Resistance against anti-CD19 and anti-BCMA CAR T cells: Recent advances and coping strategies. <i>Translational Oncology</i> , 2022, 22, 101459.	1.7	8
498	Zanubrutinib in lymphoproliferative disorders: a comprehensive review. <i>Therapeutic Advances in Hematology</i> , 2022, 13, 204062072210939.	1.1	7
499	Systematic Review of Available CAR-T Cell Trials around the World. <i>Cancers</i> , 2022, 14, 2667.	1.7	31
500	CAR-T Cells Shoot for New Targets: Novel Approaches to Boost Adoptive Cell Therapy for B Cell-Derived Malignancies. <i>Cells</i> , 2022, 11, 1804.	1.8	1
501	Allogeneic Stem Cell Transplantation in Mantle Cell Lymphoma; Insights into Its Potential Role in the Era of New Immunotherapeutic and Targeted Therapies: The GETH/GELTAMO Experience. <i>Cancers</i> , 2022, 14, 2673.	1.7	4
502	Use of long-term corticosteroids in patients treated with CAR T-cell therapy. <i>Journal of Oncology Pharmacy Practice</i> , 2023, 29, 473-476.	0.5	2
503	Longitudinal Collection of Patient-Reported Outcomes and Activity Data during CAR-T Therapy: Feasibility, Acceptability, and Data Visualization. <i>Cancers</i> , 2022, 14, 2742.	1.7	6
504	Cost-effectiveness analysis of KTE-X19 CAR T therapy versus real-world standard of care in patients with relapsed/refractory mantle cell lymphoma post BTKi in England. <i>Journal of Medical Economics</i> , 2022, 25, 730-740.	1.0	2
505	Bispecific targeting of CD20 and CD19 increases polyfunctionality of chimeric antigen receptor T-cell products in B-cell malignancies. <i>Cytotherapy</i> , 2022, 24, 767-773.	0.3	10
506	BTK Inhibitors and CAR T-Cell Therapy in Treating Mantle Cell Lymphoma—Finding a Dancing Partner. <i>Current Oncology Reports</i> , 2022, 24, 1299-1311.	1.8	10
507	Mantle Cell Lymphoma: the Role of Risk-Adapted Therapy and Treatment of Relapsed Disease. <i>Current Oncology Reports</i> , 0, , .	1.8	2
508	Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study. <i>Journal of Clinical Oncology</i> , 2023, 41, 555-567.	0.8	82
509	Novel strategies for the mitigation of cytokine release syndrome induced by T cell engaging therapies with a focus on the use of kinase inhibitors. <i>Oncolmmunology</i> , 2022, 11, .	2.1	15
510	Cytokine release syndrome and relevant factors of CD19 targeted chimeric antigen receptor T cell therapy in relapsed/refractory B cell hematological malignancies. <i>Transfusion and Apheresis Science</i> , 2022, 61, 103473.	0.5	1
511	Therapeutic Management of Lymphoma: Conventional Strategies and Overcoming Treatment Barriers with Nanotherapeutics.. <i>Current Cancer Therapy Reviews</i> , 2022, 18, .	0.2	0
512	The potential of pirtobrutinib in multiple B-cell malignancies. <i>Therapeutic Advances in Hematology</i> , 2022, 13, 204062072211016.	1.1	12
513	Immunotherapy for Pediatric Acute Lymphoblastic Leukemia: Recent Advances and Future Perspectives. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
514	CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	55

#	ARTICLE	IF	CITATIONS
515	Introducing innovative cellular therapies into the clinic: a 2-year retrospective experience of a chimeric antigen receptor T-cell programme at a single centre in Switzerland. , 2022, 152, .		5
516	Cardiovascular Toxicities with Chimeric Antigen Receptor T-cell Therapy. <i>Current Cardiology Reviews</i> , 2022, 18, .	0.6	1
517	Thrombopoietin receptor agonist for treating bone marrow aplasia following anti-CD19 CAR-T cellsâ€”single-center experience. <i>Annals of Hematology</i> , 2022, 101, 1769-1776.	0.8	13
518	Recent advances and clinical pharmacology aspects of Chimeric Antigen Receptor (CAR) Tâ€”cellular therapy development. <i>Clinical and Translational Science</i> , 2022, 15, 2057-2074.	1.5	9
519	Barriers to Chimeric Antigen Receptor T-Cell (CAR-T) Therapies in Clinical Practice. <i>Pharmaceutical Medicine</i> , 2022, 36, 163-171.	1.0	19
520	Chimeric Antigen Receptor T-Cells: An Overview of Concepts, Applications, Limitations, and Proposed Solutions. <i>Frontiers in Bioengineering and Biotechnology</i> , 0, 10, .	2.0	33
521	Autonomous push buttonâ€”controlled rapid insulin release from a piezoelectrically activated subcutaneous cell implant. <i>Science Advances</i> , 2022, 8, .	4.7	14
522	A long-acting interleukin-7, rhIL-7-hyFc, enhances CAR T cell expansion, persistence, and anti-tumor activity. <i>Nature Communications</i> , 2022, 13, .	5.8	29
523	Fertility and CAR T-cells: Current practice and future directions. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 605.e1-605.e8.	0.6	5

524

#	ARTICLE	IF	CITATIONS
533	Chidamide and sintilimab combination in diffuse large B-cell lymphoma progressing after chimeric antigen receptor T therapy. <i>World Journal of Clinical Cases</i> , 2022, 10, 6555-6562.	0.3	2
534	Engineering off-the-shelf universal CAR T cells: A silver lining in the cloud. <i>Cytokine</i> , 2022, 156, 155920.	1.4	4
535	InÂvivo generation of CAR T cells in the presence of human myeloid cells. <i>Molecular Therapy - Methods and Clinical Development</i> , 2022, 26, 144-156.	1.8	8
536	Chimeric antigen receptor T cells and management of toxicities: implications of biomarkers. , 2022, , 245-281.		0
537	Stem cell transplantation for lymphoma. <i>Journal of Illusion</i> , 2022, 11, 140-147.	0.0	0
539	Resource utilization for chimeric antigen receptor T cell therapy versus autologous hematopoietic cell transplantation in patients with B cell lymphoma. <i>Annals of Hematology</i> , 2022, 101, 1755-1767.	0.8	2
540	Feasibility of outpatient administration of axicabtagene ciloleucel and brexucabtagene autoleucel using telemedicine tools: The Vanderbilt experience. <i>British Journal of Haematology</i> , 2022, 198, 1073-1075.	1.2	9
541	Current Status and Perspectives of Dual-Targeting Chimeric Antigen Receptor T-Cell Therapy for the Treatment of Hematological Malignancies. <i>Cancers</i> , 2022, 14, 3230.	1.7	23
542	Tumor Microenvironment and Immunotherapy-Based Approaches in Mantle Cell Lymphoma. <i>Cancers</i> , 2022, 14, 3229.	1.7	7
543	Trogocytosis and fratricide killing impede MSLN-directed CAR T cell functionality. <i>Oncolmunology</i> , 2022, 11, .	2.1	9
544	Real-World Experience and Optimization of Outpatient Chimeric Antigen Receptor T Cell Therapy. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 583-585.	0.6	6
545	Mantle-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2022, 386, 2495-2506.	13.9	44
546	Influence of Culture Conditions on Ex Vivo Expansion of T Lymphocytes and Their Function for Therapy: Current Insights and Open Questions. <i>Frontiers in Bioengineering and Biotechnology</i> , 0, 10, .	2.0	4
547	Tumor immunotherapy: Mechanisms and clinical applications. , 2022, 1, .		2
548	Antigen glycosylation regulates efficacy of CAR T cells targeting CD19. <i>Nature Communications</i> , 2022, 13, .	5.8	21
549	Targeting the Microenvironment for Treating Multiple Myeloma. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7627.	1.8	9
550	Impact of Chronic Kidney Disease and Acute Kidney Injury on Safety and Outcomes of CAR T-Cell Therapy in Lymphoma Patients. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, 863-868.	0.2	3
552	Ibrutinib improves survival compared with chemotherapy in mantle cell lymphoma with central nervous system relapse. <i>Blood</i> , 2022, 140, 1907-1916.	0.6	22

#	ARTICLE	IF	CITATIONS
553	Socioeconomic and Racial Disparity in Chimeric antigen receptor T cell (CAR) Therapy Access. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 345-346.	0.6	2
554	A novel antibody-TCR (AbTCR) T-cell therapy is safe and effective against CD19-positive relapsed/refractory B-cell lymphoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 2757-2769.	1.2	4
555	Clinical trials for chimeric antigen receptor T-cell therapy: lessons learned and future directions. <i>Current Opinion in Hematology</i> , 2022, 29, 225-232.	1.2	3
556	Infectious complications, immune reconstitution, and infection prophylaxis after CD19 chimeric antigen receptor T-cell therapy. <i>Bone Marrow Transplantation</i> , 2022, 57, 1477-1488.	1.3	28
557	Evaluating the Therapeutic Potential of Idecabtagene Vicleucel in the Treatment of Multiple Myeloma: Evidence to Date. <i>OncoTargets and Therapy</i> , 0, Volume 15, 799-813.	1.0	3
558	Discovery of a Transferrin Receptor 1-Binding Aptamer and Its Application in Cancer Cell Depletion for Adoptive T-Cell Therapy Manufacturing. <i>Journal of the American Chemical Society</i> , 2022, 144, 13851-13864.	6.6	20
559	Natural killer cells in antitumour adoptive cell immunotherapy. <i>Nature Reviews Cancer</i> , 2022, 22, 557-575.	12.8	208
560	Therapy-related myeloid neoplasms following chimeric antigen receptor T-cell therapy for Non-Hodgkin Lymphoma. <i>Blood Cancer Journal</i> , 2022, 12, .	2.8	15
561	CAR T-cells in relapsed Burkitt lymphoma – a promising test drive in a rare disease. <i>Leukemia and Lymphoma</i> , 0, , 1-2.	0.6	1
562	CAR T-cell therapy for mantle cell lymphoma with central nervous system relapse. <i>Blood Advances</i> , 2023, 7, 375-378.	2.5	10
563	Preclinical In Vitro and In Vivo Models for Adoptive Cell Therapy of Cancer. <i>Cancer Journal (Sudbury,)</i> Tj ETQqO 0 0 rBT /Overlock 10 Tf 5	1.0	2
564	Enhancing adoptive T cell therapy for solid tumor with cell-surface anchored immune checkpoint inhibitor nanogels. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2022, , 102591.	1.7	2
565	Multidimensional single-cell analysis identifies a role for CD2-CD58 interactions in clinical antitumor T cell responses. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	26
566	Modulation of BCL-2 in Both T Cells and Tumor Cells to Enhance Chimeric Antigen Receptor T-cell Immunotherapy against Cancer. <i>Cancer Discovery</i> , 2022, 12, 2372-2391.	7.7	19
567	Addendum to British Society for Haematology Guideline for the management of mantle cell lymphoma, 2018 (<i>Br. J. Haematol.</i> 2018; 182: 46–62): Risk assessment of potential <sc>CAR</sc> T candidates receiving a covalent <sc>BTK</sc> inhibitor for relapsed/refractory disease. <i>British Journal of Haematology</i> , 2022, 199, 40-44.	1.2	3
568	Recommendation for <i>TP53</i> mutation testing in newly diagnosed mantle cell lymphoma: a statement from working groups sponsored by the Victorian Comprehensive Cancer Centre. <i>Internal Medicine Journal</i> , 2022, 52, 1286-1287.	0.5	0
570	Chimeric Antigen Receptor-T Cell Therapy. <i>Korean Journal of Medicine</i> , 2022, 97, 229-237.	0.1	0
571	Understanding CAR T-cell-tumor interactions: Paving the way for successful clinical outcomes. <i>Med</i> , 2022, 3, 538-564.	2.2	11

#	ARTICLE	IF	CITATIONS
572	Combination strategies to optimize the efficacy of chimeric antigen receptor T cell therapy in haematological malignancies. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	13
573	Overcoming tumor resistance mechanisms in CAR-NK cell therapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	22
574	Size-dependent activation of CAR-T cells. <i>Science Immunology</i> , 2022, 7, .	5.6	36
575	Safety and feasibility of stem cell boost as a salvage therapy for severe hematotoxicity after CD19 CAR T-cell therapy. <i>Blood Advances</i> , 2022, 6, 4719-4725.	2.5	25
576	Microraft arrays for <sc>serialâ€killer CD19</sc> chimeric antigen receptor T cells and single cell isolation. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2023, 103, 208-220.	1.1	2
577	Cardiotoxicity Associated With Chimeric Antigen Receptor (CAR)-T Cell Therapy for Hematologic Malignancies: A Systematic Review. <i>Cureus</i> , 2022, , .	0.2	2
579	CAR T-Based Therapies in Lymphoma: A Review of Current Practice and Perspectives. <i>Biomedicines</i> , 2022, 10, 1960.	1.4	5
580	Cancer Immunotherapy and Delivery System: An Update. <i>Pharmaceutics</i> , 2022, 14, 1630.	2.0	12
581	Induced expression of CCL19 promotes the anti-tumor ability of CAR-T cells by increasing their infiltration ability. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
582	Regulatory T cells (Tregs) in lymphoid malignancies and the impact of novel therapies. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	6
583	Pneumococcal Conjugate Vaccine Does Not Induce Humoral Response When Administrated Within the Six Months After CD19 CAR T-Cell Therapy. <i>Transplantation and Cellular Therapy</i> , 2023, 29, 277.e1-277.e9.	0.6	9
584	Treatment Landscape of Relapsed/Refractory Mantle Cell Lymphoma: An Updated Review. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, e1019-e1031.	0.2	7
585	Outcomes for Recurrent Mantle Cell Lymphoma Post-Ibrutinib Therapy: A Retrospective Cohort Study from a Japanese Administrative Database. <i>Advances in Therapy</i> , 2022, 39, 4792-4807.	1.3	4
586	The Clinical Impact of Precisely Defining Mantle Cell Lymphoma: Contributions of Elaine Jaffe. <i>Hemato</i> , 2022, 3, 508-517.	0.2	0
587	Ixazomib With or Without Rituximab Following Maintenance Autologous Stem Cell Transplant in Mantle Cell Lymphoma: A Single-Center Phase I Trial. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, e1084-e1091.	0.2	1
588	Strategies to overcome CAR-T cell resistance in clinical work: A single-institute experience. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	1
589	Assessing the role of radiotherapy in patients with refractory or relapsed high-grade B-cell lymphomas treated with CAR T-cell therapy. <i>Radiotherapy and Oncology</i> , 2022, 175, 65-72.	0.3	13
590	Development of anti-somatostatin receptors CAR T cells for treatment of neuroendocrine tumors. , 2022, 10, e004854.		8

#	ARTICLE	IF	CITATIONS
591	CAR-T cellsâ€”Real-time experience applying CAR-T cellsâ€”What we have learned so far. Memo - Magazine of European Medical Oncology, 2022, 15, 173-175.	0.3	0
592	EXABS-225-NQ Next Questions: Mantle Cell Lymphoma. Clinical Lymphoma, Myeloma and Leukemia, 2022, 22, S113-S114.	0.2	0
593	Nano-drug delivery systems for T cell-based immunotherapy. Nano Today, 2022, 46, 101621.	6.2	13
594	EXABS-205-MCL Immunotherapeutic Options for Patients with MCL Who Progress on BTK Inhibitors. Clinical Lymphoma, Myeloma and Leukemia, 2022, 22, S97-S98.	0.2	0
595	Applying a clinical lens to animal models of CAR-T cell therapies. Molecular Therapy - Methods and Clinical Development, 2022, 27, 17-31.	1.8	18
596	Relapse Mechanism and Treatment Strategy After Chimeric Antigen Receptor T-Cell Therapy in Treating B-Cell Hematological Malignancies. Technology in Cancer Research and Treatment, 2022, 21, 153303382211184.	0.8	2
597	Intracellular Cardiac Signaling Pathways Altered by Cancer Therapies. , 2022, , 111-173.		0
599	Investigation of the risk factors to predict cytokine release syndrome in relapsed or refractory B-cell acute lymphoblastic leukemia patients receiving IL-6 knocking down anti-CD19 chimeric antigen receptor T-cell therapy. Frontiers in Immunology, 0, 13, .	2.2	4
600	Chimeric antigen receptor T cell therapy for cancer: clinical applications and practical considerations. BMJ, The, 0, , e068956.	3.0	4
601	Targeted and cellular therapies in lymphoma: Mechanisms of escape and innovative strategies. Frontiers in Oncology, 0, 12, .	1.3	2
602	CAR-T cell potency: from structural elements to vector backbone components. Biomarker Research, 2022, 10, .	2.8	14
603	Longâ€”term outcomes and predictors of early response, late relapse, and survival for patients treated with bispecific <sc>LV20</sc>.19 <sc>CAR</sc> Tâ€”cells. American Journal of Hematology, 2022, 97, 1580-1588.	2.0	5
604	A rapid and sensitive UPLCâ€”MS/MS method for the determination of zanubrutinib in beagle plasma and its application in pharmacokinetics. Biomedical Chromatography, 0, , .	0.8	1
605	Experiences with Glofitamab Administration following CAR T Therapy in Patients with Relapsed Mantle Cell Lymphoma. Cells, 2022, 11, 2747.	1.8	4
606	Association of bridging therapy utilization with clinical outcomes in patients receiving chimeric antigen receptor (CAR) T-cell therapy. , 2022, 10, e004567.		3
607	Risk of infection in patients with hematological malignancies receiving CAR T-cell therapy: systematic review and meta-analysis. Expert Review of Anti-Infective Therapy, 2022, 20, 1455-1476.	2.0	8
608	Lymphoma tumor burden before chimeric antigen receptor T-Cell treatment: RECIL vs. Lugano vs. metabolic tumor assessment. Frontiers in Oncology, 0, 12, .	1.3	5
609	Current updates on generations, approvals, and clinical trials of CAR T-cell therapy. Human Vaccines and Immunotherapeutics, 2022, 18, .	1.4	21

#	ARTICLE	IF	CITATIONS
610	Clinical Strategies for Enhancing the Efficacy of CAR T-Cell Therapy for Hematological Malignancies. <i>Cancers</i> , 2022, 14, 4452.	1.7	1
611	IL12 immune therapy clinical trial review: Novel strategies for avoiding CRS-associated cytokines. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	12
612	Impact of Cytomegalovirus Replication in Patients with Aggressive B Cell Lymphoma Treated with Chimeric Antigen Receptor T Cell Therapy. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 851.e1-851.e8.	0.6	10
613	Paving the road to make chimeric antigen receptorâ€”cell therapy effective against solid tumors. <i>Cancer Science</i> , 2022, 113, 4020-4029.	1.7	2
614	Metabolic Imaging in B-Cell Lymphomas during CAR-T Cell Therapy. <i>Cancers</i> , 2022, 14, 4700.	1.7	6
615	Price and Prejudice? The Value of Chimeric Antigen Receptor (CAR) T-Cell Therapy. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 12366.	1.2	17
616	Recent findings on chimeric antigen receptor (CAR)-engineered immune cell therapy in solid tumors and hematological malignancies. <i>Stem Cell Research and Therapy</i> , 2022, 13, .	2.4	11
617	TIGIT is the central player in T-cell suppression associated with CAR T-cell relapse in mantle cell lymphoma. <i>Molecular Cancer</i> , 2022, 21, .	7.9	22
618	A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma. <i>Nature Medicine</i> , 2022, 28, 2145-2154.	15.2	106
619	The correlation factors and prognostic significance of coagulation disorders after chimeric antigen receptor T cell therapy in hematological malignancies: a cohort study. <i>Annals of Translational Medicine</i> , 2022, 10, 975-975.	0.7	2
620	Co-Stimulatory Receptor Signaling in CAR-T Cells. <i>Biomolecules</i> , 2022, 12, 1303.	1.8	11
621	Practical aspects of chimeric antigen receptor T-cell administration: From commercial to point-of-care manufacturing. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	9
622	Cardiovascular disease and chimeric antigen receptor cellular therapy. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	1
623	Cytopenia after chimeric antigen receptor T cell immunotherapy in relapsed or refractory lymphoma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
624	Therapeutic Advances in Immunotherapies for Hematological Malignancies. <i>International Journal of Molecular Sciences</i> , 2022, 23, 11526.	1.8	6
625	Advances in CAR T-cell therapy in bile duct, pancreatic, and gastric cancers. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
626	BTK inhibitors in the treatment of hematological malignancies and inflammatory diseases: mechanisms and clinical studies. <i>Journal of Hematology and Oncology</i> , 2022, 15, .	6.9	35
627	Fever Characteristics and Impact on Safety and Efficacy of Chimeric Antigen Receptor T-Cell Therapy. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2023, 23, e14-e18.	0.2	1

#	ARTICLE	IF	CITATIONS
628	Adverse Cardiac Effects of CAR T-Cell Therapy: Characteristics, Surveillance, Management, and Future Research Directions. <i>Technology in Cancer Research and Treatment</i> , 2022, 21, 153303382211329.	0.8	2
630	The journey of CAR-T therapy in hematological malignancies. <i>Molecular Cancer</i> , 2022, 21, .	7.9	45
631	Role of Immunotherapy in the Treatment of Cancer: A Systematic Review. <i>Cancers</i> , 2022, 14, 5205.	1.7	5
632	A FOXO1-dependent transcription network is a targetable vulnerability of mantle cell lymphomas. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	8
633	Is There Still a Role for Transplant for Patients with Mantle Cell Lymphoma (MCL) in the Era of CAR-T Cell Therapy?. <i>Current Treatment Options in Oncology</i> , 2022, 23, 1614-1625.	1.3	4
634	EBV-associated diseases: Current therapeutics and emerging technologies. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	15
636	Whole-process management of complications during CART therapy. , 2022, 1, .		0
638	Tumor buster - where will the CAR-T cell therapy "missile" go?. <i>Molecular Cancer</i> , 2022, 21, .	7.9	23
639	Aggressive, early resistant and relapsed mantle cell lymphoma distinct extrinsic microenvironment highlighted by transcriptome analysis. <i>EJHaem</i> , 2022, 3, 1165-1171.	0.4	2
641	Next generations of CAR-T cells - new therapeutic opportunities in hematology?. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	24
642	Anti-Apoptotic c-FLIP Reduces the Anti-Tumour Activity of Chimeric Antigen Receptor T Cells. <i>Cancers</i> , 2022, 14, 4854.	1.7	1
644	Genome-edited allogeneic donor "universal" chimeric antigen receptor T cells. <i>Blood</i> , 2023, 141, 835-845.	0.6	11
645	Frontline treatment approaches in TP53-aberrant mantle cell lymphoma. <i>Leukemia and Lymphoma</i> , 2023, 64, 230-233.	0.6	1
646	Combination of ibrutinib and venetoclax followed by Chimeric Antigen Receptor T-cell therapy in the first line of treatment in an elderly patient with mantle cell lymphoma with hyperleukocytosis and mutation in the TP53 gene. <i>Gematologiya I Transfuziologiya</i> , 2022, 67, 441-452.	0.1	0
647	Chimeric Antigen Receptor Immunotherapy for Solid Tumors: Choosing the Right Ingredients for the Perfect Recipe. <i>Cancers</i> , 2022, 14, 5351.	1.7	1
648	Real-world experience among patients with relapsed/refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor failure in Europe: The SCHOLAR retrospective chart review study. <i>British Journal of Haematology</i> , 2023, 202, 749-759.	1.2	10
649	Advances in immunotherapy for glioblastoma multiforme. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	24
650	Migratory Engineering of T Cells for Cancer Therapy. <i>Vaccines</i> , 2022, 10, 1845.	2.1	8

#	ARTICLE	IF	CITATIONS
651	Bispecific antibodies for the treatment of B-cell lymphoma: promises, unknowns, and opportunities. <i>Blood</i> , 2023, 141, 467-480.	0.6	33
652	Chimeric Antigen Receptor T-Cell Therapy: What We Expect Soon. <i>International Journal of Molecular Sciences</i> , 2022, 23, 13332.	1.8	10
654	Administration of granulocyte-macrophage colony-stimulating factor enhanced chimeric antigen receptor T-cell expansion and cellular immunity recovery without inducing cytokine release syndrome. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	1
655	Toxicities following CAR-T therapy for hematological malignancies. <i>Cancer Treatment Reviews</i> , 2022, 111, 102479.	3.4	13
656	Multispecific CAR T Cells Deprive Lymphomas of Escape via Antigen Loss. <i>Annual Review of Medicine</i> , 2023, 74, 279-291.	5.0	10
657	A novel polymer-conjugated human IL-15 improves efficacy of CD19-targeted CAR T-cell immunotherapy. <i>Blood Advances</i> , 2023, 7, 2479-2493.	2.5	4
658	Clinical Pharmacology and Determinants of Response to UCART19, an Allogeneic Anti-CD19 CAR-T Cell Product, in Adult B-cell Acute Lymphoblastic Leukemia. <i>Cancer Research Communications</i> , 2022, 2, 1520-1531.	0.7	6
659	Ibrutinib in mantle cell lymphoma: a real-world retrospective multi-center analysis of 77 patients treated in the Czech Republic. <i>Annals of Hematology</i> , 2023, 102, 107-115.	0.8	2
660	Non-viral precision T cell receptor replacement for personalized cell therapy. <i>Nature</i> , 2023, 615, 687-696.	13.7	85
661	Natural killer cells in clinical development as non-engineered, engineered, and combination therapies. <i>Journal of Hematology and Oncology</i> , 2022, 15, .	6.9	37
662	Cytopenias following anti-CD19 chimeric antigen receptor (CAR) T cell therapy: a systematic analysis for contributing factors. <i>Annals of Medicine</i> , 2022, 54, 2950-2964.	1.5	5
663	Switchable targeting of solid tumors by BsCAR T cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	13
664	Immunophenotypic transformation in relapsed/refractory mantle cell lymphoma treated with human anti-CD5 chimeric antigen receptor T cells: A Case Report. , 0, 1, .		1
666	Pre-clinical efficacy of CD20-targeted chimeric antigen receptor T cells for non-Hodgkin's lymphoma. <i>Discover Oncology</i> , 2022, 13, .	0.8	0
667	Changing the Tune for CAR T-Cell Therapy: A Music City Experience in Remote Patient Monitoring. <i>Oncology Issues</i> , 2022, 37, 20-24.	0.0	1
668	Preclinical models for development of immune oncology therapies. <i>Immuno-oncology Insights</i> , 2022, 03, 396-398.	0.0	2
669	Engineered T cell therapy for viral and non-viral epithelial cancers. <i>Cancer Cell</i> , 2023, 41, 58-69.	7.7	13
670	Gene and Cell Therapy: How to Build a BioDrug. <i>Pediatric Oncology</i> , 2022, , 51-88.	0.5	0

#	ARTICLE	IF	CITATIONS
671	CAR T-cell therapy for follicular lymphoma and mantle cell lymphoma. <i>Therapeutic Advances in Hematology</i> , 2022, 13, 204062072211421.	1.1	5
672	Polymer- and lipid-based gene delivery technology for CAR T cell therapy. <i>Journal of Controlled Release</i> , 2023, 353, 196-215.	4.8	11
673	Transcriptomic analysis of the innate immune response to in vitro transfection of plasmid DNA. <i>Molecular Therapy - Nucleic Acids</i> , 2023, 31, 43-56.	2.3	3
674	The role of CAR-T cell therapy as second line in diffuse large B-cell lymphoma. <i>Therapeutic Advances in Hematology</i> , 2022, 13, 204062072211415.	1.1	3
675	Immunotherapy of Lymphoma. , 2022, , 1-24.		0
677	Chimeric antigen receptor T-cell therapy for T-ALL and AML. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	11
678	Immunotherapy approaches for rare pediatric solid tumors: advances and future directions. <i>Current Opinion in Pediatrics</i> , 2023, 35, 63-74.	1.0	0
679	Treating Multiple Myeloma in the Context of the Bone Marrow Microenvironment. <i>Current Oncology</i> , 2022, 29, 8975-9005.	0.9	9
680	Multiplexed engineering and precision gene editing in cellular immunotherapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
681	“A.B.C.” of Immunotherapy in Hematological Malignancies Promise and Perils. <i>Indian Journal of Medical and Paediatric Oncology</i> , 0, , .	0.1	0
682	Prognostic value of the International Metabolic Prognostic Index for lymphoma patients receiving chimeric antigen receptor T-cell therapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2023, 50, 1406-1413.	3.3	7
683	Two-year follow-up of KTE-X19 in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia in ZUMA-3 and its contextualization with SCHOLAR-3, an external historical control study. <i>Journal of Hematology and Oncology</i> , 2022, 15, .	6.9	16
684	Radiotherapy as a means to increase the efficacy of T-cell therapy in solid tumors. <i>Oncolimmunology</i> , 2023, 12, .	2.1	7
685	Anti-CD19 chimeric antigen receptor T cells secreting anti-PD-L1 single-chain variable fragment attenuate PD-L1 mediated T cell inhibition. <i>International Immunopharmacology</i> , 2022, 113, 109442.	1.7	2
686	Recurrent Mantle Cell Lymphoma Isolated to the Testis After 19-Year Remission: A Case Report and Review of the Literature. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, , .	0.2	0
687	Pirtobrutinib and venetoclax combination overcomes resistance to targeted and chimeric antigen receptor T-cell therapy in aggressive mantle cell lymphoma. <i>Haematologica</i> , 2023, 108, 1412-1416.	1.7	2
688	Cancer Immunotherapy Beyond Checkpoint Blockade. <i>JACC: CardioOncology</i> , 2022, 4, 563-578.	1.7	1
689	Dose-response correlation for CAR-T cells: a systematic review of clinical studies. , 2022, 10, e005678.		15

#	ARTICLE	IF	CITATIONS
690	Efficient clinical-grade $\hat{\beta}$ -retroviral vector purification by high-speed centrifugation for CAR T \hat{c} ell manufacturing. <i>Molecular Therapy - Methods and Clinical Development</i> , 2023, 28, 116-128.	1.8	0
691	Comprehensive clinical evaluation of CAR-T cell immunotherapy for solid tumors: a path moving forward or a dead end?. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 2709-2734.	1.2	6
692	Coated recombinant target protein helps explore IL-1RAP CAR T-cell functionality in vitro. <i>Immunologic Research</i> , 2023, 71, 276-282.	1.3	4
694	Phase I CART Clinical Trials Review. <i>Anticancer Research</i> , 2022, 42, 5673-5684.	0.5	0
695	Development of a Core Set of Patient- and Caregiver-Reported Signs and Symptoms to Facilitate Early Recognition of Acute Chimeric Antigen Receptor T-Cell Therapy Toxicities. <i>JCO Oncology Practice</i> , 2023, 19, e407-e416.	1.4	2
696	Acute Kidney Injury in Cancer Immunotherapy Recipients. <i>Cells</i> , 2022, 11, 3991.	1.8	4
697	Targeting TGF- $\hat{\beta}$ 2 signaling in the multiple myeloma microenvironment: Steering CARs and T cells in the right direction. <i>Frontiers in Cell and Developmental Biology</i> , 0, 10, .	1.8	5
698	Compromised antigen binding and signaling interfere with bispecific CD19 and CD79a chimeric antigen receptor function. <i>Blood Advances</i> , 0, , .	2.5	2
699	A comparison of the International Consensus and 5th World Health Organization classifications of mature B-cell lymphomas. <i>Leukemia</i> , 2023, 37, 18-34.	3.3	21
700	PET/CT in Non-Hodgkin Lymphoma: An Update. <i>Seminars in Nuclear Medicine</i> , 2023, 53, 320-351.	2.5	13
701	High-Dose Cytarabine and Autologous Stem-Cell Transplantation in Mantle Cell Lymphoma: Long-Term Follow-Up of the Randomized Mantle Cell Lymphoma Younger Trial of the European Mantle Cell Lymphoma Network. <i>Journal of Clinical Oncology</i> , 2023, 41, 479-484.	0.8	10
702	SSTR2 as an anatomical imaging marker and a safety switch to monitor and manage CAR T cell toxicity. <i>Scientific Reports</i> , 2022, 12, .	1.6	4
703	Where Do We Stand with Immunotherapy for Advanced Pancreatic Ductal Adenocarcinoma: A Synopsis of Clinical Outcomes. <i>Biomedicines</i> , 2022, 10, 3196.	1.4	6
704	Cardiotoxicity of T-Cell Antineoplastic Therapies. <i>JACC: CardioOncology</i> , 2022, 4, 616-623.	1.7	10
705	The place of allogeneic stem cell transplantation in aggressive B-cell non-Hodgkin lymphoma in the era of CAR-T-cell therapy. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	0
706	Evaluating the Patient with Neurotoxicity after Chimeric Antigen Receptor T-cell Therapy. <i>Current Treatment Options in Oncology</i> , 2022, 23, 1845-1860.	1.3	2
707	What is the role of up-front autologous stem cell transplantation in mantle cell lymphoma?. <i>Hematology American Society of Hematology Education Program</i> , 2022, 2022, 155-162.	0.9	2
708	Do CART and Allogeneic Stem Cell Transplant Both Have a Place in Lymphoid Neoplasms?. <i>International Journal of Molecular Sciences</i> , 2023, 24, 1045.	1.8	2

#	ARTICLE	IF	CITATIONS
709	Current state of CAR-T therapy for T-cell malignancies. <i>Therapeutic Advances in Hematology</i> , 2022, 13, 204062072211430.	1.1	11
710	Multifocal demyelinating leukoencephalopathy and oligodendroglial lineage cell loss with immune effector cell-associated neurotoxicity syndrome (ICANS) following CD19 CAR T-cell therapy for mantle cell lymphoma. <i>Journal of Neuropathology and Experimental Neurology</i> , 2023, 82, 160-168.	0.9	2
711	Modulation of the gut microbiota engages antigen cross-presentation to enhance antitumor effects of CAR T cell immunotherapy. <i>Molecular Therapy</i> , 2023, 31, 686-700.	3.7	7
714	Lisocabtagene maraleucel in the treatment of relapsed/refractory large B-cell lymphoma. <i>Future Oncology</i> , 2023, 19, 19-28.	1.1	4
715	Molecular and therapeutic effect of CRISPR in treating cancer. , 2023, 40, .		2
716	CD4 CAR-T cells targeting CD19 play a key role in exacerbating cytokine release syndrome, while maintaining long-term responses. , 2023, 11, e005878.		11
717	Determinants of resistance to engineered T cell therapies targeting CD19 in large B cell lymphomas. <i>Cancer Cell</i> , 2023, 41, 210-225.e5.	7.7	32
718	Is CD19-directed chimeric antigen receptor T cell therapy a smart strategy to combat central nervous system lymphoma?. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
719	Top advances of the year: Leukemia. <i>Cancer</i> , 0, , .	2.0	0
720	Bridging Radiation Rapidly and Effectively Cyto-reduces High-Risk Relapsed/Refractory Aggressive B Cell Lymphomas Prior to Chimeric Antigen Receptor T Cell Therapy. <i>Transplantation and Cellular Therapy</i> , 2023, 29, 259.e1-259.e10.	0.6	9
721	Efficacy and safety of CD22-specific and CD19/CD22-bispecific CAR-T cell therapy in patients with hematologic malignancies: A systematic review and meta-analysis. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	5
722	Outcomes among Patients with Mantle Cell Lymphoma Post-Covalent BTK Inhibitor Therapy in the United States: A Real-World Electronic Medical Records Study. <i>Advances in Hematology</i> , 2022, 2022, 1-8.	0.6	2
723	Impact of Precision Medicine in Oncology. <i>Cancer Journal (Sudbury, Mass)</i> , 2023, 29, 15-19.	1.0	1
724	Lymphodepletion and cellular immunotherapy. , 2023, , 181-196.		0
725	Cellular and Vaccine-Based Immunotherapy for Hematologic Malignancies. , 2023, , .		0
726	Identifying effect modifiers of CAR-T cell therapeutic efficacy: a systematic review and individual patient data meta-analysis protocol. <i>Systematic Reviews</i> , 2023, 12, .	2.5	0
728	Advancing CAR T cell therapy through the use of multidimensional omics data. <i>Nature Reviews Clinical Oncology</i> , 2023, 20, 211-228.	12.5	30
729	Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma in Standard-of-Care Practice: Results From the US Lymphoma CAR T Consortium. <i>Journal of Clinical Oncology</i> , 2023, 41, 2594-2606.	0.8	37

#	ARTICLE	IF	CITATIONS
730	A phase I dose-escalation study of neoantigen-activated haploidentical T cell therapy for the treatment of relapsed or refractory peripheral T-cell lymphoma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
731	CAR-T cells for cancer immunotherapy. <i>Chinese Chemical Letters</i> , 2023, 34, 108202.	4.8	3
732	Anakinra for Refractory Cytokine Release Syndrome or Immune Effector Cell-Associated Neurotoxicity Syndrome after Chimeric Antigen Receptor T Cell Therapy. <i>Transplantation and Cellular Therapy</i> , 2023, 29, 430-437.	0.6	15
733	Highlights into historical and current immune interventions for cancer. <i>International Immunopharmacology</i> , 2023, 117, 109882.	1.7	2
734	Metabolic challenges and interventions in CAR T cell therapy. <i>Science Immunology</i> , 2023, 8, .	5.6	13
735	Cytotoxicity of CD19-CAR-NK92 cells is primarily mediated via perforin/granzyme pathway. <i>Cancer Immunology, Immunotherapy</i> , 2023, 72, 2573-2583.	2.0	0
736	Prognostic value of pre-infusion tumor growth rate for patients with lymphoma receiving chimeric antigen receptor T-cell therapy. <i>Cytotherapy</i> , 2023, 25, 986-992.	0.3	3
737	Advances in chimeric antigen receptor T cells therapy in the treatment of breast cancer. <i>Biomedicine and Pharmacotherapy</i> , 2023, 162, 114609.	2.5	4
738	Chimeric Antigen Receptor T-cell Therapy in Cancer: A Critical Review. <i>Current Drug Research Reviews</i> , 2023, 15, 241-261.	0.7	2
739	Associations of granulocyte colony-stimulating factor with toxicities and efficacy of chimeric antigen receptor T-cell therapy in relapsed or refractory multiple myeloma. <i>Cytotherapy</i> , 2023, 25, 653-658.	0.3	3
740	Identifying Early Infections in the Setting of CRS With Routine and Exploratory Serum Proteomics and the HT10 Score Following CD19 CAR-T for Relapsed/Refractory B-NHL. <i>HemaSphere</i> , 2023, 7, e858.	1.2	10
741	Chimeric Antigen Receptor T-cell Therapy in Hematologic Malignancies and Patient-reported Outcomes: A Scoping Review. <i>HemaSphere</i> , 2022, 6, e802.	1.2	7
743	Immunotherapy for Hematological Cancers. , 2023, , 1-15.		0
744	Treatment approaches for patients with TP53-mutated mantle cell lymphoma. <i>Lancet Haematology</i> , the, 2023, 10, e142-e154.	2.2	6
745	Cellular and humoral immunotherapy in children, adolescents and young adults with non-Hodgkin lymphoma. <i>Best Practice and Research in Clinical Haematology</i> , 2023, 36, 101442.	0.7	2
746	Safety evaluation of axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma. <i>Expert Opinion on Drug Safety</i> , 2023, 22, 5-15.	1.0	1
747	Tuned activation of MSLN-CAR T cells induces superior antitumor responses in ovarian cancer models. , 2023, 11, e005691.		9
748	Long-Term Survival of Patients with Mantle Cell Lymphoma after Total Body Irradiation, High-Dose Chemotherapy and Stem Cell Transplantation: A Monocenter Study. <i>Cancers</i> , 2023, 15, 983.	1.7	1

#	ARTICLE	IF	CITATIONS
749	Procalcitonin as a biomarker for predicting bacterial infection in chimeric antigen receptor T cell therapy recipients. <i>Cancer Medicine</i> , 2023, 12, 9228-9235.	1.3	7
750	Chimeric Antigen Receptor T-Cell Therapy and Hematopoiesis. <i>Cells</i> , 2023, 12, 531.	1.8	1
751	Nanomodified Switch Induced Precise and Moderate Activation of CAR T Cells for Solid Tumors. <i>Advanced Science</i> , 2023, 10, .	5.6	2
752	CAR-T Cell Therapy: the Efficacy and Toxicity Balance. <i>Current Hematologic Malignancy Reports</i> , 2023, 18, 9-18.	1.2	15
753	A systematic framework for predictive biomarkers in immune effector cell-associated neurotoxicity syndrome. <i>Frontiers in Neurology</i> , 0, 14, .	1.1	4
754	Early Use of Corticosteroids following CAR T-Cell Therapy Correlates with Reduced Risk of High-Grade CRS without Negative Impact on Neurotoxicity or Treatment Outcome. <i>Biomolecules</i> , 2023, 13, 382.	1.8	8
755	A Multicenter Analysis of the Outcomes with Venetoclax in Patients with Relapsed Mantle Cell Lymphoma. <i>Blood Advances</i> , 0, , .	2.5	1
756	Chimeric antigen receptor-T cell therapy-related cardiotoxicity in adults and children cancer patients: A clinical appraisal. <i>Frontiers in Cardiovascular Medicine</i> , 0, 10, .	1.1	4
757	CAR immune cells: design principles, resistance and the next generation. <i>Nature</i> , 2023, 614, 635-648.	13.7	96
758	Potential links between the microbiota and T cell immunity determine the tumor cell fate. <i>Cell Death and Disease</i> , 2023, 14, .	2.7	4
759	An Overview of Cytokine Release Syndrome and Other Side Effects of CAR-T Cell Therapy. <i>Praxis</i> , 2023, 112, 189-193.	0.2	2
760	Gene-targeted therapies: Overview and implications. <i>American Journal of Medical Genetics, Part C: Seminars in Medical Genetics</i> , 2023, 193, 13-18.	0.7	1
762	Infectious complications of chimeric antigen receptor (CAR) T-cell therapies. <i>Seminars in Hematology</i> , 2023, 60, 52-58.	1.8	2
763	Cardiotoxicities of Novel Therapies in Hematologic Malignancies: Chimeric Antigen Receptor T-Cell Therapy and Bispecific T-Cell Engager Therapy. <i>JCO Oncology Practice</i> , 0, , .	1.4	0
765	Impact of Preemptive Use of Tocilizumab on Chimeric Antigen Receptor T Cell Outcomes in Non-Hodgkin Lymphoma. <i>Transplantation and Cellular Therapy</i> , 2023, 29, 429.e1-429.e6.	0.6	2
766	Fungal Infections Associated with CD19-Targeted Chimeric Antigen Receptor T Cell Therapy. <i>Current Fungal Infection Reports</i> , 0, , .	0.9	0
767	Infectious Complications of Targeted Therapies for Solid Cancers or Leukemias/Lymphomas. <i>Cancers</i> , 2023, 15, 1989.	1.7	2
768	Bridging the Gap: Early Transition and Hybrid Models of Care to Improve Access to Chimeric Antigen Receptor T Cell Therapy. <i>Transplantation and Cellular Therapy</i> , 2023, 29, 399-402.	0.6	2

#	ARTICLE	IF	CITATIONS
769	Phase I Trial of Autologous RNA-electroporated cMET-directed CAR T Cells Administered Intravenously in Patients with Melanoma and Breast Carcinoma. <i>Cancer Research Communications</i> , 2023, 3, 821-829.	0.7	9
770	CAR T-Cell therapy for the management of mantle cell lymphoma. <i>Molecular Cancer</i> , 2023, 22, .	7.9	11
771	Prognostic value of early bone marrow MRD status in CAR-T therapy for myeloma. <i>Blood Cancer Journal</i> , 2023, 13, .	2.8	6
772	CAR T-cell-associated neurotoxicity in central nervous system hematologic disease: Is it still a concern?. <i>Frontiers in Neurology</i> , 0, 14, .	1.1	6
773	Immunotherapy for Acute Leukemia. , 2022, , 1-41.		0
774	Influence of Adipose Tissue Distribution, Sarcopenia, and Nutritional Status on Clinical Outcomes After CD19 CAR T-cell Therapy. <i>Cancer Immunology Research</i> , 2023, 11, 707-719.	1.6	7
775	Polatuzumabâ€bendamustineâ€rituximab as bridge to CD19â€directed CAR T cells in mantle cell lymphoma refractory to ibrutinib and venetoclax. <i>EJHaem</i> , 0, , .	0.4	0
776	Long-term outcomes following CAR T cell therapy: what we know so far. <i>Nature Reviews Clinical Oncology</i> , 2023, 20, 359-371.	12.5	119
777	BTK Inhibitors and Other Targeted Therapies in WaldenstrÃ¶m Macroglobulinemia. <i>Hemato</i> , 2023, 4, 135-157.	0.2	1
778	Apoptosis: a<i>Janus bifrons</i> in T-cell immunotherapy. , 2023, 11, e005967.		3
779	Bruton tyrosine kinase inhibitors preserve anti-CD19 chimeric antigen receptor T-cell functionality and reprogram tumor micro-environment in B-cell lymphoma. <i>Cytotherapy</i> , 2023, 25, 739-749.	0.3	1
780	Mechanisms of Resistance and Treatment of Relapse after CAR T-cell Therapy for Large B-cell Lymphoma and Multiple Myeloma. <i>Transplantation and Cellular Therapy</i> , 2023, 29, 418-428.	0.6	7
781	CAR-T-sejtes kezelÃ©sek a hematolÃ³giai betegsÃ©gekben. <i>Transfusio</i> , 2023, 55, 164-170.	0.0	0
782	CAR-modified immune cells as a rapidly evolving approach in the context of cancer immunotherapies. , 2023, 40, .		0
783	Mutated Flt3Lg Provides Reduced Flt3 Recycling Compared to Wild-Type Flt3Lg and Retains the Specificity of Flt3Lg-Based CAR T-Cell Targeting in AML Models. <i>International Journal of Molecular Sciences</i> , 2023, 24, 7626.	1.8	1
785	Allogeneic chimeric antigen receptor-T cells with CRISPR-disrupted programmed death-1 checkpoint exhibit enhanced functional fitness. <i>Cytotherapy</i> , 2023, 25, 750-762.	0.3	4
786	Necroptosis-related lncRNAs: establishment of a gene module and distinction between the cold and hot tumors in glioma. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	2
803	The clinical application of immuno-therapeutics. , 2024, , 237-288.e7.		0

#	ARTICLE	IF	CITATIONS
815	CAR T-Cell Therapy and Critical Care Considerations. , 2023, , 427-435.		0
832	Preparative Regimens Used in Hematopoietic Cell Transplantation and Chimeric Antigen Receptor T-Cell Therapies. , 2024, , 125-143.		0
833	Miscellaneous Complications of Chimeric Antigen Receptor T-Cell Therapy. , 2024, , 537-547.		0
834	Cytokine Release Syndrome Following CD19 Directed Chimeric Antigen Receptor T-Cell Therapy. , 2024, , 509-524.		0
835	Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma. , 2024, , 341-355.		0
836	Process and General Management of Patients Undergoing Chimeric Antigen Receptor Therapies. , 2024, , 115-122.		0
837	Chimeric Antigen Receptor Therapy in Lymphoma. , 2024, , 371-381.		0
874	Genome Editing for Engineering the Next Generation of Advanced Immune Cell Therapies. Advances in Experimental Medicine and Biology, 2023, , 85-110.	0.8	0
881	The Promise of Immunotherapeutics and Vaccines in the Treatment of Cancer. , 2023, , 1-43.		1
890	Successful treatment by CAR T-cells in multi-refractory mantle cell lymphoma with central nervous system involvement. Annals of Hematology, 2023, 102, 3295-3297.	0.8	2
892	Immunotherapy in hematologic malignancies: achievements, challenges and future prospects. Signal Transduction and Targeted Therapy, 2023, 8, .	7.1	5
899	Drug delivery systems for CRISPR-based genome editors. Nature Reviews Drug Discovery, 2023, 22, 875-894.	21.5	9
922	Gene Editing and Gene Therapy in Oncology. , 2023, , 155-180.		4
954	T cell receptor therapeutics: immunological targeting of the intracellular cancer proteome. Nature Reviews Drug Discovery, 2023, 22, 996-1017.	21.5	7
958	CD8 T-cell subsets: heterogeneity, functions, and therapeutic potential. Experimental and Molecular Medicine, 2023, 55, 2287-2299.	3.2	7
964	Neurotoxicity of Cancer Immunotherapies Including CAR T Cell Therapy. Current Neurology and Neuroscience Reports, 0, , .	2.0	0
1002	Technologien und Lösungsansätze für die effiziente Herstellung von Zelltherapeutika für die CAR-Immuntherapie. , 2023, , 123-137.		0
1003	Mantelzellymphom. , 2023, , 179-196.		0

#	ARTICLE	IF	CITATIONS
1004	Engineered CAR-T cells: An immunotherapeutic approach for cancer treatment and beyond. <i>Advances in Protein Chemistry and Structural Biology</i> , 2024, , .	1.0	0
1007	Mantle Cell Lymphoma. , 2023, , .		0
1028	Waldenstrom Macroglobulinemia. , 2024, , .		0
1031	The critical role of endothelial cell in the toxicity associated with chimeric antigen receptor T cell therapy and intervention strategies. <i>Annals of Hematology</i> , 0, , .	0.8	0
1035	Indolente (niedrig maligne) Non-Hodgkin-Lymphome. , 2024, , 491-544.		0